Top

Abhishek Maiti, MD

Department of Leukemia, Division of Cancer Medicine

About Dr. Abhishek Maiti

Dr. Abhishek Maiti is an Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He graduated from Nil Ratan Sircar Medical College in India, and completed internal medicine residency at the University of Texas, Houston, followed by a fellowship in hematology/oncology at MD Anderson Cancer Center. Dr. Maiti's patient care and research focuses on developing novel therapies for leukemias. He has authored several peer-reviewed publications in leading medical journals and presented his research at national and international meetings. His work has received recognition from the American Society of Clinical Oncology, the European Hematology Association, the American Society of Hematology, the Society for Translational Oncology, and others. He has received prestigious national and international awards including the ASCO Young Investigator Award, the Future Leaders in Hematology Award, Leuka International Scholarship, ASCO Endowed Merit Award, the Shannon Timmins Endowed Fellowship, among others.

ASCO: Developing effective combination therapies for leukemia

Present Title & Affiliation

Primary Appointment

Assistant Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

Education & Training

Degree-Granting Education

2010	Nilratan Sircar Medical College and Hospital, Kolkata, IN, MD

Postgraduate Training

2017-2020	Clinical Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas
2014-2017	Clinical Residency, The University of Texas Health Science Center, Houston, Texas
2010-2011	Clinical Internship, Nilratan Sircar Medical College and Hospital, Kolkata

Board Certifications

2020	Oncology, American Board of Medical Specialties
2020	Hematology, American Board of Medical Specialties
2017	American Board of Internal Medicine

Experience & Service

Institutional Committee Activities

Member, Junior Faculty Academic Career Development Committee, 2024 - Present

Workgroup Member, Chronic Myeloid Leukemia - Adult, 2024 - Present

Member, Institutional Review Board #3, 2023 - Present

Reviewer / Member, Scientific Review Committee # 1, 2022 - Present

Member, Senate Research Affairs Committee, 2021 - Present

Member, Academic and Planning Committee - Division of Education & Training, 2021 - Present

Abstract Reviewer, Academic Review Committee - Division of Education & Training, 2021 - 2021

Co-Chair, Emil J Freireich Leukemia Hematology Grand Rounds, 2021 - Present

Member, Adult Acute Myeloid Leukemia, 2020 - Present

Member, Institutional Review Board, 2020 - 2023

Member, Graduate Medical Education Committee, UTHSCH, 2017 - 2018

Member, House Staff Senate, 2015 - 2016

Resident Member, Texas Medical Association Cancer Committee, 2015 - 2017

Resident Member, Harris Health/LBJ Hospital Cancer Committee, 2015 - 2017

Resident Member, Memorial Hermann Hospital Cancer Committee, 2015 - 2017

Honors & Awards

	National Merit Scholarship, Government of India
	Indian Council of Medical Research, Short Term Studentship
	National Science Academies’ Summer Research Fellowship
	Best Paper for Pulmonary Medicine Poster Session, International Medical Students’ Research Conference
	Best Presentation, Resident and Fellow Section, American Medical Association Annual Research Symposium
	Future Leaders in Hematology Award for Clinical Research
	Best Research Poster, 2nd Position, American College of Physicians Texas Associates Day
	Best Abstract Award, Society of Hematologic Oncology
	Abstract Achievement Award, American Society of Hematology
	Methods in Clinical Cancer Research Workshop, AACR/ASCO
	Leuka International Scholarship, European School of Hematology
	AACR Molecular Biology in Clinical Oncology Workshop, AACR
	Shannon Timmins Endowed Fellowship in Leukemia Research
	Society for Translational Oncology Fellows’ Award
	ASCO Endowed Merit Award, ASCO Bristol-Myers Squibb
	EHA Travel Grant Award, European Hematology Association
	FDA Fellows' Day Workshop
	Kimberly Patterson Fellowship for Excellence in Leukemia Research
	ASCO Young Investigator Award, Conquer Cancer Foundation
	SITC Clinical Immuno-Oncology Network Workshop, Society for Immunotherapy of Cancer
	Prioritizing Research Innovation and Mentoring Excellence (PRIME) Award, University of Texas MD Anderson Cancer Center

Professional Memberships

European Haematology Association (EHA)

Junior Member, 2020 - Present

Sigma Xi, Scientific Research Honor Society

Full Member, 2020 - Present

American Association of Cancer Research (AACR)

Associate Member, 2018 - Present

American Society of Hematology (ASH)

Resident Member, 2016 - Present

American Society of Clinical Oncology (ASCO)

Resident Member, 2016 - Present

Texas Medical Association

Resident Member, 2015 - 2017

American Medical Association

Resident Member, 2015 - 2017

Harris County Medical Society

Resident Member, 2014 - 2017

American College of Physicians (ACP)

Resident member, 2014 - Present

Selected Publications

Peer-Reviewed Articles

Jen WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McCue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti Abhishek, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer None(None):None. e-Pub 2024. PMID: 39584789.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. PMID: 38695144.
Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G, Tomalin LE, Cruz-Rodriguez N, Wang T, Olszewska M, Olivier E, Jaud M, Nadorp B, Kroger B, Hu F, Silverman L, Chung SS, Wagenblast E, Chaligne R, Eisfeld AK, Demircioglu D, Landau DA, Lito P, Papaemmanuil E, DiNardo CD, Hasson D, Konopleva M, Papapetrou EP. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature None(None):None, 2024. PMID: 39478230.
Ravandi F, Senapati J, Jain N, Short NJ, Kadia T, Borthakur G, Konopleva M, Wierda W, Huang X, Maiti A, Issa G, Balkin H, Garris R, Ferrajoli A, Garcia-Manero G, Alvarado Y, Kebriaei P, Jabbour E, Kantarjian HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia None(None):None, 2024. PMID: 39322712.
Sango J, Carcamo S, Sirenko M, Maiti A, Hager M, Ulukaya G, Tomalin L, CruzRodriguez N, Wang T, Olszewska M, Olivier E, Jaud M, Nadorp B, Kroger B, Hu F, Silverman L, Chung S, Wagenblast E, Chaligne R, Eisfeld AK, Demircioglu D, Landau D, Lito P, Papaemmanuil E, Courtney CD, Hasson DH, Konopleva M, Papapetrou EP. RAS-mutant AML LSCs originate from GMPs and drive clinical resistance to BH3 2 mimetics. Nature None(None):None. e-Pub 2024. PMID: None.
Cieniewicz B, Oliveira E, Saxton M, Torabi D, Bhatta A, Kukutla P, Arballo A, Yang Z, Yu B, Fate M, Ning H, Corey L, Maiti A, Corey D. Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia. Clin Cancer Res 30(9):1878-1888, 2024. PMID: 38451195.
Gruszczynska A, Maiti A, Miller CA, Ramakrishnan SM, Link DC, Uy GL, Petti AA, Hayes K, DiNardo CD, Ravandi F, Ley TJ, Spencer DH, Gao F, Konopleva MY, Welch JS. Molecular responses in decitabine-and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes. Haematologica 109(8):2653-2659, 2024. PMID: 38618679.
Gruszczynska A, Maiti A, Miller CA, Ramakrishnan SM, Link DC, Uy GL, Petti AA, Hayes K, DiNardo CD, Ravandi F, Ley TJ, Spencer DH, Gao F, Konopleva MY, Welch JS. Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes. Haematologica, 2024. PMID: 38618679.
Bazinet, A, Garcia-Manero, G, Short, NJ, Alvarado, Y, Bataller, A, Abuasab, T, Islam, R, Montalbano, K, Issa, GC, Maiti, A, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Montalban Bravo, G, Rausch, CR, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia. The Lancet Haematology 11(4):e276-e286, 2024. PMID: 38452788.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Advances 8(4):927-935, 2024. PMID: 38113472.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. PMID: 38113472.
Senapati, J, Urrutia, S, Loghavi, S, Short, NJ, Issa, GC, Maiti, A, Abbas, HA, Daver, N, Pemmaraju, N, Pierce, S, Chien, KS, Sasaki, K, Kadia, TM, Hammond, DE, Borthakur, G, Patel, KP, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G, DiNardo, C. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. PMID: 37441846.
Short, NJ, Ong, F, Ravandi, F, Nogueras Gonzalez, G, Kadia, TM, Daver, N, DiNardo, C, Konopleva, M, Borthakur, G, Oran, B, Al-Atrash, G, Mehta, RS, Jabbour, EJ, Yilmaz, M, Issa, GC, Maiti, A, Champlin, RE, Kantarjian, HM, Shpall, E, Popat, UR. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Advances 7(14):3573-3581, 2023. PMID: 37104058.
Pouleau, B, Estoppey, C, Suere, P, Nallet, E, Laurendon, A, Monney, T, Pais Ferreira, D, Drake, A, Carretero-Iglesia, L, Macoin, J, Berret, J, Pihlgren, M, Doucey, MA, Gudi, GS, Menon, V, Udupa, V, Maiti, A, Borthakur, G, Srivastava, A, Blein, S, Mbow, ML, Matthes, T, Kaya, Z, Edwards, CM, Edwards, JR, Menoret, E, Kervoëlen, C, Pellat-Deceunynck, C, Moreau, P, Zhukovsky, E, Perro, M, Chimen, M. Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma. Blood 142(3):260-273, 2023. PMID: 37192303.
Bazinet, A, Kadia, TM, Short, NJ, Borthakur, G, Wang, SA, Wang, W, Loghavi, S, Jorgensen, JL, Patel, KP, DiNardo, C, Daver, N, Alvarado, Y, Haddad, FG, Pierce, S, Gonzalez, GN, Maiti, A, Sasaki, K, Yilmaz, M, Thompson, PA, Wierda, WG, Garcia-Manero, G, Andreeff, M, Jabbour, EJ, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Advances 7(13):3284-3296, 2023. PMID: 36884300.
Pouleau B, Estoppey C, Suere P, Nallet E, Laurendon A, Monney T, Ferreira D, Drake A, Carretero-iglesia L, Macoin J, Berret J, Pihlgren M, Doucey MA, Gudi G, Menon V, Udupa V, Maiti A, Borthakur G, Srivastava A, Blein S, Mbow ML, Matthes T, Kaya Z, Edwards C, Edwards J, Menoret E, Kervoelen C, Pellat-Deceunynck C, Moreau P, Zhukovsky E, Perro M, Chimen M. Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma. Blood 2023 July 20(142(3)):260-73, 2023. PMID: None.
DiNardo CD, Venugopal S, Lachowiez CA, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway HE, Sekeres MA, Sukkur A, Hammond D, Chien KS, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia TM, Short NJ, Daver NG, Borthakur G, Ravandi F, Kantarjian HM, Patel BJ, DeZern AE, Roboz GJ, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378-2387, 2023. e-Pub 2022. PMID: 35973199.
Fedorov K, Maiti A, Konopleva MY. Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions. Cancers 15(8):2312, 2023. PMID: 37190240.
Issa GC, Bidikian A, Venugopal S, Konopleva MY, DiNardo CD, Kadia TM, Borthakur G, Jabbour EJ, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce SR, Takahashi K, Tang G, Loghavi S, Patel KP, Andreeff M, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian HM, Daver NG. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2022. PMID: 36322818.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, 7 SL, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2023. e-Pub 2023. PMID: 38113472.
Zeng Z, Maiti A, Herbrich S, Cai T, Cavazos A, Manzella T, Ma H, Hayes K, Matthews J, DiNardo CD, Daver NG, Konopleva MY. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia. Cancer 129(4):531-540, 2023. e-Pub 2022. PMID: 36477735.
Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Gonzalez GN, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv 7(13):3284-96, 2023. PMID: 36884300.
Estoppey C, Suere P, Nallet E, Laurendon A, Monney T, Ferreira DP, Drake A, Carretero-Iglesia L, Macoin J, Berret J, Pihlgren M, Doucey M, Gudi GS, Menon V, Udupa V, Maiti A, Borthakur G, Srivastava A, Blein S, M Lamine Mbow M, Matthes T, Kaya Z, Edwards CM, Edwards JR, Menoret E, Kervoëlen C, 0 CP, 0 PM, Zhukovsky E, Perro M, Chimen M. Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma. Blood 142(3):260-273, 2023. PMID: 37192303.
Maiti A, Pal AJ. Spin-Selective Charge Transport in Lead-Free Chiral Perovskites: The Key towards High-Anisotropy in Circularly-Polarized Light Detection. Angew Chem Int Ed Engl 61(52):e202214161, 2022. PMID: 36325645.
Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol 97(12):1560-1567, 2022. e-Pub 2022. PMID: 36087091.
Maiti A, Daver NG. Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions. J Clin Oncol 40(34):JCO2201505, 2022. e-Pub 2022. PMID: 36070541.
Rausch CR, DiPippo AJ, Jiang Y, DiNardo CD, Kadia T, Maiti A, Montalban-Bravo G, Ravandi F, Kontoyiannis DP. Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies. Clin Infect Dis 75(9):1503-1510, 2022. e-Pub 2022. PMID: 35325094.
Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol 97(11):E408-E411, 2022. e-Pub 2022. PMID: 36054774.
Maiti A, DiNardo CD, Qiao W, al E. Ten-day Decitabine with Venetoclax vs. Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. Cancer 127(22):4213-20, 2022. PMID: 34343352.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
Maiti A, Pal AJ. Quasi-2D Ruddlesden-Popper Lead Halide Perovskites: How Edge Matters. J Phys Chem Lett 13(42):9875-9882, 2022. PMID: 36251849.
Venugopal, S, Kantarjian, HM, Maiti, A, Short, NJ, Montalban Bravo, G, Alvarado, Y, Chien, KS, Kanagal Shamanna, R, Pemmaraju, N, Daver, N, Kadia, TM, Borthakur, G, Jabbour, EJ, Garcia-Manero, G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia 22:S321, 2022. PMID: 36163977.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. PMID: 35483396.
Maiti A, Daver NG. A nonstick marrow may help to fry leukemia. Blood 139(8):1119-1121, 2022. PMID: 35201330.
Goswamy, R, Ajufo, HO, Maiti, A, Brown, RE, Juneja, HS, Apostolidou, E. Refractory Hydroa Vacciniforme-Like Lymphoma. International Journal of Hematology-Oncology and Stem Cell Research 16(3):174-180, 2022. PMID: None.
Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
Maiti A, Konopleva MY. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia. Cancer J 28(1):2-13, 2022. PMID: 35072368.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta Haematol 145(5):529-536, 2022. e-Pub 2022. PMID: 35717939.
Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma 62(14):3501-3505, 2021. e-Pub 2021. PMID: 34474640.
Maiti A, Daver NG. Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia. Clin Cancer Res 27(21):5739-5741, 2021. e-Pub 2021. PMID: 34470774.
Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer 127(22):4213-4220, 2021. e-Pub 2021. PMID: 34343352.
Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 127(20):3772-3781, 2021. e-Pub 2021. PMID: 34255353.
Dan S, Maiti A, Chatterjee S, Pal AJ. Origin of bandgap bowing in Cs(2)Na(1-x)Ag(x)BiCl(6)double perovskite solid-state alloys: a paradigm through scanning tunneling spectroscopy. J Phys Condens Matter 33(48):None, 2021. PMID: 34479226.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia. Am J Hematol 96(8):1000-1007, 2021. e-Pub 2021. PMID: 33991360.
Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol 14(1):94, 2021. e-Pub 2021. PMID: 34130720.
Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol 96(5):589-598, 2021. e-Pub 2021. PMID: 33639000.
Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol 96(5):E154-E157, 2021. e-Pub 2021. PMID: 33580980.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. PMID: 33792630.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. PMID: 33885753.
Diao S, Nichols ED, DiNardo C, Konopleva M, Ning J, Qiao W, Maiti A, DiPippo AJ. Incidence of Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia Undergoing Low-Intensity Induction with Venetoclax. Am J Hematol 96(3):E65-E68, 2021. e-Pub 2020. PMID: 33259075.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2020. PMID: 33264443.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
Bhugra P, Maiti A. A 44-year-old man with cough, arthralgia, and fever. Eur J Intern Med 77:119-120, 2020. e-Pub 2020. PMID: 32418704.
Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer 126(7):1502-1511, 2020. e-Pub 2020. PMID: 31999839.
Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. PMID: 32330243.
Ball S, Das A, Vutthikraivit W, Edwards PJ, Hardwicke F, Short NJ, Borthakur G, Maiti A. Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Lymphoma Myeloma Leuk 20(2):87-97.e5, 2020. e-Pub 2019. PMID: 31787589.
Maiti A, Khatun S, Pal AJ. Rashba Band Splitting in CH(3)NH(3)PbI(3): An Insight from Spin-Polarized Scanning Tunneling Spectroscopy. Nano Lett 20(1):292-299, 2020. PMID: 31841346.
Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol 143(6):567-573, 2020. e-Pub 2020. PMID: 32289808.
Ko H, Yan M, Gupta R, Kebbel K, Maiti A, Song J, Nates J, Overman MJ. Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit. Oncologist 24(4):483-490, 2019. e-Pub 2018. PMID: 30518614.
Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19(3):142-148.e1, 2019. e-Pub 2018. PMID: 30635233.
Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol 37(1):96-102, 2019. e-Pub 2018. PMID: 30153704.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2018. PMID: 30545576.
Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer 16(1):e47-e57, 2018. e-Pub 2017. PMID: 28870517.
Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose P. First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol 2:1-6, 2018. e-Pub 2018. PMID: 31080940.
Maiti A, Short NJ, Verstovsek S, Powers CA, Fullmer CA, Reyes SR, Bueso-Ramos CE. Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis. Leuk Lymphoma 58(10):2508-2510, 2017. e-Pub 2017. PMID: 28264600.
Simkins A, Maiti A, Cherian SV, Trujillo DO, Estrada-Y-Martin RM. Mounier-Kuhn syndrome. Postgrad Med J 93(1104):642, 2017. e-Pub 2017. PMID: 28596443.
Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O'Brien S, Kantarjian H. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma 58(9):1-6, 2017. e-Pub 2017. PMID: 28278723.
Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol 92(9):924-928, 2017. e-Pub 2017. PMID: 28556489.
Maiti A, Wanger A, Chavez V, Smith DT. Acute appendicitis caused by Schistosoma japonicum. J Infect Public Health 10(3):331-333, 2017. e-Pub 2016. PMID: 27283925.
Maiti A, Cherian SV, Estrada-Y-Martin RM. Thoracic splenosis mimicking pleural mass: the importance of clinical history. QJM 110(4):241-242, 2017. PMID: 28073932.
Maiti A, Cortes JE, Brown YD, Kantarjian HM. Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leuk Lymphoma 58(3):722-725, 2017. e-Pub 2016. PMID: 27658536.
Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology 92(1):14-20, 2017. e-Pub 2016. PMID: 27802448.
Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol 91(12):1221-1226, 2016. e-Pub 2016. PMID: 27474808.
Maiti A, Das A, Smith DT. Phlegmasia cerulea dolens. Postgrad Med J 92(1093):690, 2016. e-Pub 2016. PMID: 27274083.
Maiti A, Chatterjee S. Turner syndrome: fifteen years' experience in India. J Obstet Gynaecol India 64(Suppl 1):121-3, 2014. e-Pub 2013. PMID: 25404835.
Maiti A, Chatterjee S. Neuropsychiatric manifestations and their outcomes in chronic hypocalcaemia. J Indian Med Assoc 111(3):174-7, 2013. PMID: 24592758.
Maiti A, Nandi K, Chatterjee S. Management of gestational diabetes mellitus in a public hospital setting in India: lessons from a minimalist approach. Diabetes Res Clin Pract 95(2):e34-6, 2012. e-Pub 2011. PMID: 22129654.
Maiti, A, Chakraborti, A, Chakraborty, P, Mishra, S. Subclinical haemorrhagic tendency exists in patients with β-thalassaemia major in early childhood. Australasian Medical Journal 5(2):152-155, 2012. PMID: None.
Maiti A, Chakraborti A, Chakraborty P, Mishra S. Subclinical haemorrhagic tendency exists in patients with β-thalassaemia major in early childhood. Australas Med J 5(2):152-5, 2012. e-Pub 2012. PMID: 22905058.
Maiti A, Chatterjee S. Congenital adrenal hyperplasia: an Indian experience. J Paediatr Child Health 47(12):883-7, 2011. e-Pub 2011. PMID: 21658148.

Manuals, Teaching Aids, Other Teaching Publications

Daver N, Maiti A. Immunotherapies and Cellular Therapies for Patients with Acute Myeloid Leukemia. MD Anderson Cancer Center, 2021.
Maiti A, Ravandi F. Oral Therapies for Acute Myeloid Leukemia. MDACC, 2021.

Abstracts

Yamatani K, Saito K, Maiti A, Khasawneh A, Paran FJ, Suzuki T, Okamoto T, Hayes K, Zeng Z, DiNardo CD, Andreeff M, Konopleva M, Tabe Y. Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus RNA Signaling in AML Cells and Induces T Cell Activation. Blood 144(Supplement 1):1389, 2024. PMID: None.
Rausch CR, Almanza-Huante E, Jen W, Montalban-Bravo G, Ravandi F, Chien KS, Short NJ, Daver N, DiNardo CD, Maiti A, Jabbour JE, Issa GC, Garcia-Manero G, Kantarjian HM, Kadia TM. Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML). Blood 144(S):4262, 2024. PMID: None.
Marvin-Peek J, Atluri H, Short NJ, Maiti A, Takahashi K, Loghavi S, Lachowiez CA, Valero YA, Montalban-Bravo G, Sasaki K, Haddad FG, Issa GC, Masarova L, Abbas HA, Andreeff M, Borthakur G, Mullin J, Tippett GD, Chien KS, Hammond D, Ishizawa J, Jain N, Reville PK, Swaminathan M, Yilmaz M, Daver N, Kadia TM, Ravandi F, Garcia-Manero G, Kantarjian HM, DiNardo CD. Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials. Blood 144(Supplement 1):2883, 2024. PMID: None.
Marvin-Peek J, Kantarjian HM, Jen W, Borthakur G, Daver N, Maiti A, Short NJ, Kornblau SM, Pemmaraju N, Kugler E, Bazinet A, Alvarado-Valero Y, Abbas HA, Garcia-Manero G, Popat U, Shpall EJ, Ravandi F, DiNardo CD, Kadia TM. Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax. Blood 144(Supplement 1):3572, 2024. PMID: None.
Marvin-Peek J, Garcia JS, Borthakur G, Garcia-Manero G, Short NJ, Kadia TM, Loghavi S, Masarova L, Daver N, Maiti A, Takahashi K, Sasaki K, Hammond D, Tippett GD, Wilson D, Chien KS, Bose P, Reville PK, Lachowiez CA, Jain AG, Issa GC, Jain N, Montalban-Bravo G, Luskin MR, Carraway HE, Ravandi F, Kantarjian HM, DiNardo CD. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update. Blood 144(S):219, 2024. PMID: None.
Yilmaz M, Muftuoglu M, Short NJ, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Pemmaraju N, Valero YA, Maiti A, Konopleva M, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike A, Patel KP, Tang G, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Takahashi K, Andreeff M, Ravandi F, Kantarjian HM, Daver N. Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML. Blood 144(Supplement 1):4263, 2024. PMID: None.
Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, Short NJ, McCall D, Pike A, Tan S, Kammerer B, Marshal A, Yilmaz M, Kadia TM, Pemmaraju N, Ohanian M, Abbas HA, Maiti A, Bazinet A, Jabbour E, Sasaki K, Borthakur G, Montalban-Bravo G, Jain N, Valero YA, Ravandi F, Garcia-Manero G, Andreeff M, Kantarjian HM. Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML. Blood 144(S):216, 2024. PMID: None.
Maiti A, Post SM, DiNardo CD, Daver N, Kadia TM, Pike A, Hwang H, Huang X, Andreeff M, Ravandi F, CHOI J, Ahn H, Kim J, Nam K, Borthakur G. Phase 1 Study of AXL/MER/CSF1R Inhibitor Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia. Blood 144(Supplement 1):5994, 2024. PMID: None.
Goulart H, Kantarjian HM, Daver N, Yilmaz M, Garcia-Manero G, Chien KS, Burger JA, Pemmaraju N, DiNardo CD, Short NJ, Montalban-Bravo G, Maiti A, Hammond D, Issa GC, Jabbour E, Ravandi F, Kadia TM. A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia. Blood 144(Supplement 1):2901, 2024. PMID: None.
Marvin-Peek J, Jen W, Short NJ, Issa GC, Yilmaz M, Montalban-Bravo G, Bazinet A, Sasaki K, Maiti A, Borthakur G, Hammond D, Chien KS, Abbas HA, Pemmaraju N, Garcia-Manero G, Jabbour E, Ravandi F, Kadia TM, Daver N, DiNardo CD. Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease. Blood 144(Supplement 1):2851, 2024. PMID: None.
Croden J, Hammond D, Chien KS, Maiti A, Tippett GD, Montalban-Bravo G, Morales M, Short NJ, Abbas HA, Issa GC, Kadia TM, Borthakur G, Ravandi F, DiNardo CD. Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 144(Supplement 1):4271, 2024. PMID: None.
Kundu, Rupayan, Kal, Niladri, Singh, Abhay, Mukherjee, Sudipto, Maiti, Abhishek, Ball, Somedeb, Jain, Akriti G. Epidemiological Trends in Incidence, Death and Associated Risk Factors of Leukemia 1990-2021 and Projection to 2040. Blood 144(Supplement 1):1477, 2024. PMID: None.
Wu SY, Sasaki K, Fang PQ, Short NJ, Gunther JR, Dong W, Damron EP, Nasr LF, Boyce DR, Maiti A, Pinnix CC, Issa GC, Jain N, DiNardo CD, Ravandi F, Jabbour E, Kebriaei P, Dabaja BS. CNS Involvement in Adult Patients with B-Cell Acute Lymphoblastic Leukemia. Blood 144(Supplement 1):4182, 2024. PMID: None.
Maiti A, Daver N, Johnson WT, Goyal G, Broome CM, Gohil S, Laar JV, Jimenez JL, McCall D, Lane H, Kim B, Panicker S, Patou G, Moore S, Mangal B, Covert K, Parry GC, Dong K, Allen C, Iyer SP. ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis. Blood 144(Supplement 1):805, 2024. PMID: None.
Nguyen D, Ravandi F, Wang SA, Jorgensen JL, WANG W, Loghavi S, Lee J, Bachireddy P, DiNardo CD, Chien KS, Montalban-Bravo G, Issa GC, Maiti A, Valero YA, Daver N, Jabbour E, Kadia TM, Pemmaraju N, Yilmaz M, Nguyen DT, Popat U, Shpall EJ, Garcia-Manero G, Kantarjian H, Short NJ. Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML. Blood 144(S):1007, 2024. PMID: None.
Uyanik MS, Garcia-Manero G, Maiti A, Ravandi F, Chien KS, Hammond D, Bazinet A, Schneider H, Hendrickson S, Pierce S, Kantarjian HM, Pemmaraju N, Montalban-Bravo G. Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes. Blood 144(Supplement 1):1842, 2024. PMID: None.
Bazinet A, Garcia-Manero G, Bataller A, Valero YA, Yilmaz M, Jabbour E, Montalban-Bravo G, Pemmaraju N, Issa GC, Short NJ, Kadia TM, Jain N, Masarova L, Daver N, Hammond D, Borthakur G, Maiti A, Takahashi K, Chien KS, Kornblau SM, Abbas HA, Ohanian M, Senapati J, DiNardo CD, Kantarjian HM, Ravandi F. Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy. Blood 144(S):2896, 2024. PMID: None.
Khasawneh A, Paran FJ, Maiti A, Wang B, Hayes K, DiNardo CD, Andreeff M, Abbas HA, Konopleva M, Tabe Y. Transcriptomic Signature of Resistance to Decitabine/Venetoclax in AML Patients. Blood 144(Supplement 1):2766, 2024. PMID: None.
Croden J, Marvin-Peek J, Konopleva M, Borthakur G, Daver N, Abbas HA, Takahashi K, Sasaki K, Garcia-Manero G, Jain N, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Valero YA, Kornblau SM, Ravandi F, Kantarjian H, Kadia TM, DiNardo CD. Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax. Blood 144(Supplement 1):6126, 2024. PMID: None.
Nishida Y, Mizuno H, Ayoub E, Sugihara E, Ostermann LB, Khazaei S, Scruggs D, Mak PY, Ke B, Carter BZ, Maiti A, Ma L, Andreeff M. Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells. Blood 144(Supplement 1):2755, 2024. PMID: None.
Eckstrom A, Rao A, Siddiqui M, Tyagi A, Zeng J, Tan WK, Maiti A, Battula VL. Donor-Derived Variable Delta 2 (Vδ2) Gamma Delta (γδ) T Cells: A Promising Off-the-Shelf Therapeutic Strategy for Acute Myeloid Leukemia. Blood 144(Supplement 1):7186, 2024. PMID: None.
Maiti A, Dumas P, Peterlin P, Morillo D, Torregrosa-Diaz J, Ulrickson M, Koller P, Gassart AD, Valentin E, Mairesse M, Brune P, Lemmens K, Olive D, Braun S, Daver N, Garciaz S. ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction. Blood 142(Supplement 1):2876, 2024. e-Pub 2024. PMID: None.
Arora S, Senapati J, Loghavi S, Reville PK, Wang B, Kadia TM, DiNardo CD, Pemmaraju N, Yilmaz M, Jabbour JE, Short NJ, Montalban-Bravo G, Maiti A, Tang G, Sasaki K, Borthakur G, Alvarez J, Pierce S, Nogueras González GM, Ning J, Issa GC, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA, Daver N. Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse. Blood 144(S):735, 2024. PMID: None.
Bazinet A, Daver N, Ravandi F, Short NJ, Yilmaz M, Ohanian M, Ishizawa J, Maiti A, DiNardo CD, Masarova L, Wierda WG, Chien KS, Jabbour E, Hammond D, Haddad FG, Sasaki K, Bataller A, Bull-Linderman D, Borthakur G, Garcia-Manero G, Kantarjian HM, Kadia TM. Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission. Blood 144(Supplement 1):4277, 2024. PMID: None.
Hammond D, Sasaki K, Takahashi K, Shpall EJ, Popat U, Oran B, Al-Atrash G, Patel KK, Westin JR, Neelapu SS, Alvarado-Valero Y, Chien KS, Daver N, Montalban-Bravo G, Maiti A, Yilmaz M, Jabbour E, Pemmaraju N, Swaminathan M, Ishizawa J, Jain N, Ferrajoli A, Ravandi F, Kornblau SM, Borthakur G, Garcia-Manero G, Kantarjian HM, Reville PK, Abbas HA. Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies. Blood 144(Supplement 1):1837, 2024. PMID: None.
Nguyen D, Kantarjian H, Short NJ, Jain N, Haddad FG, Yilmaz M, Ferrajoli A, Kadia TM, Valero YA, Maiti A, Zoghbi M, Senapati J, Garris R, Zhao M, Konopleva M, Ravandi F, Jabbour E. Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia. Blood 144(Supplement 1):1439, 2024. PMID: None.
Senapati J, Kantarjian HM, Jain N, Short NJ, Kadia TM, Borthakur G, Konopleva M, Wierda W, Maiti A, Issa GC, Huang X, Balkin HS, Garris RS, Ferrajoli A, Garcia-Manero G, Alvarado Y, Kebriaei P, Jabbour E, Ravandi F. ALL-748 Venetoclax Added to Hyper-CVAD-Nelarabine and Pegylated Asparagine Improves Outcomes in Patients With T-Cell Acute Lymphoblastic Leukemia/Lymphoma. Clinical Lymphoma Myeloma and Leukemia 24(S):S283, 2024. PMID: None.
Senapati J, Kantarjian HM, Jain N, Short NJ, Kadia TM, Borthakur G, Konopleva M, Wierda W, Maiti A, Issa GC, Huang X, Balkin HS, Garris RS, Ferrajoli A, Garcia-Manero G, Alvarado Y, Kebriaei P, Jabbour E, Ravandi F. Venetoclax Added to Hyper-CVAD-Nelarabine and Pegylated Asparagine Improves Outcomes in Patients With T-Cell Acute Lymphoblastic Leukemia/Lymphoma. Clinical Lymphoma Myeloma and Leukemia 24(Supplement 1):S164, 2024. PMID: None.
Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G, Tomalin L, Olivier E, Olszewska M, Demircioglu D, Landau D, Papaemmanuil E, DiNardo C, Hasson D, Konopleva M, Papapetrou E. 2012 – N/KRAS-MUTANT AML LSCS ORIGINATE FROM COMMITTED MYELOMONOCYTIC PROGENITORS AND DRIVE CLINICAL RESISTANCE TO VENETOCLAX. Experimental Hematology 137(Supplement):104569, 2024. PMID: None.
Maiti A, Daver N, Johnson W, Goyal G, Broome CM, Gohil S, Laar JAM, Lopez Jimenez FJ, McCall D, Lane H, Kim B, Panicker S, Patou G, Moore S, Mangal B, Covert K, Parry G, Dong K, Dao K, Allen C, Iyer S. ELA026 TARGETING OF SIRP(+) IMMUNE CELLS RESULTS IN A HIGH RESPONSE RATE AND IMPROVED 2-MONTH SURVIVAL OF REATMENT-NAÏVE MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PHASE 1 STUDY. HemaSphere 8(S1):LB3442, 2024. PMID: None.
Nishida Y, Ayoub E, Baran N, Mizuno H, Khazaei S, Ostermann L, Munir F, Baozhen, Ke, Yee MP, Carter B, Impedovo V, Tiziani S, Haferlach T, Maiti A, Mohanty V, Ken, Chen, Liandong MA, Andreeff M. (P444) TARGETING MYC BY DEGRADATION REWIRES METABOLOMICS AND INDUCES CELL KILL IN TP53 MUTANT ACUTE MYELOID LEUKEMIAS. HemaSphere 8(S1):706-707, 2024. PMID: None.
Daver NG, Maiti A, Sallman DA, Roboz GJ, Solh MM, Milano F, Strickland SA, Eghtedar A, Kanner SB, Ledergor G, Marcy D, Garner E, Francica BJ, Shaw M, Bird K, Rattan J, Zudaire E, Portella S, Vachhani P, Park JH. A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify). J Clin Oncol 42(16_suppl):TPS6586-TPS6586, 2024. PMID: None.
Arora S, Senapati J, Masarova L, Pemmaraju N, Bose P, Montalban-Bravo G, Saenz D, Halim H, Zhou L, Maiti A, Borthakur G, Kadia T, Jabbour E, Guillermo, Garcia-Manero, Kantarjian H, Daver N. (P1039) LONG TERM FOLLOW-UP RESULTS OF PHASE II CLINICAL TRIAL EVALUATING RUXOLITINIB (RUX) AND AZACITIDINE (AZA) COMBINATION THERAPY IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF). HemaSphere 8(S1):1869-1870, 2024. PMID: None.
Arora S, Senapati J, Masarova L, Pemmaraju N, Bose P, Bravo GM, Saenz DT, Halim H, Zhou L, Maiti A, Borthakur G, Kadia TM, Jabbour E, Garcia-Manero G, Kantarjian HM, Guastad Daver AN. Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF). Journal of Clinical Oncology 42(16):6572, 2024. PMID: None.
Swaminathan M, Dinardo CD, Maiti A, Pemmaraju N, Ohanian M, Daver NG, Garcia-Manero G, Issa GC, Borthakur G, Ravandi-Kashani F, Montalban-Bravo G, Kadia TM, Valero YA, Jabbour E, Short NJ, Wierda WG, Jain N, Kornblau SM, Kantarjian HM, Konopleva AM. A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS). Journal of Clinical Oncology 42(16):6549, 2024. PMID: None.
Bazinet A, Dinardo CD, Arani N, Bataller A, Rausch CR, Maiti A, Swaminathan M, Daver NG, Kadia TM, Ravandi-Kashani F, Kantarjian HM, Chraibi S, Decroocq J, Pascal L, Lebon D, Bonnet S, Gauthier N, Pages A, Botton SD, Willekens C. A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia. Journal of Clinical Oncology 42(16):6507, 2024. PMID: None.
Altomare I, Shelley A, Lu Y, Salcuni PM, Graves N, Maiti A, Govindan AR. Utility of automated data transfer for cancer clinical trials. Journal of Clinical Oncology 42(16):e23011, 2024. PMID: None.
Tyagi A, Siddiqui M, Kurth I, Takeda S, Eckstrom A, Borgman J, Maiti A, Battula VL. Targeting myeloid epithelial tyrosine kinase (MERTK) receptor in acute myeloid leukemia using a novel antibody-drug conjugate, RGX-019-MMAE. Cancer Research 84(6_Supplement):6341-6341, 2024. PMID: None.
Kim YJ, Li Z, Maiti A, Tanaka T, Uryu H, Furudate K, Hayes K, Daver N, Pemmaraju N, Kadia TM, Ravandi F, Short NJ, Ohanian M, Borthakur G, Jain N, Issa GC, Masarova L, Kornblau SM, Wierda WG, Loghavi S, Wang SA, Garcia-Manero G, Kantarjian H, DiNardo CD, Konopleva MY, Takahashi K. Abstract 3400: Single-cell proteogenomics analysis of AML samples treated with decitabine and venetoclax reveals divergent treatment escape mechanisms. Cancer Research 84(6_Supplement):3400, 2024. PMID: None.
Willekens C, Bazinet A, Chraibi S, Arani N, Bataller A, Croocq JD, Rausch C, Maiti A, Short N, Sasaki K, Swaminathan M, Daver N, Kadia T, Ravandi F, Hagop, Kantarjian, Pascal L, Lebon D, Bonnet S, Gauthier N, Khalife-Hachem S, Jean-Baptiste, Micol, Pasquier F, Christophe M, Bouscary D, Pages A, Botton SD, Dinardo C. (P590) REDUCED VENETOCLAX EXPOSURE TO 7 DAYS VS STANDARD VENETOCLAX EXPOSURE WITH HYPOMETHYLATING AGENT IN OLDER/UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COMPARISON. HemaSphere 8(S1):990-991, 2024. PMID: None.
Jen W, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Short N, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado-Valero Y, Pemmaraju N, Alessandra, Ferrajoli, Reville P, Swaminathan M, Ohanian M, Abbas H, Hammond D, Burger J, Fadi, Haddad, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Guillermo, Garcia-Manero, Kornblau S, Ravandi F, Jabbour E, Konopleva M, Mullin J, Pierce S, Hagop, Kantarjian, Dinardo C. (S136) FLAG-IDA + VENETOCLAX (VEN) IN NEWLY DIAGNOSED (ND) OR RELAPSED / REFRACTORY (RR) AML. HemaSphere 8(S1):79-80, 2024. PMID: None.
Jain N, Jabbour E, Short N, Paul S, Lovell A, Senapati J, Haddad F, Kadia T, Yilmaz M, Borthakur G, Pemmaraju N, Takahashi K, Daver N, Issa G, Alvarado Y, Maiti A, Montalban-Bravo G, Bansal D, Islam R, Wang S, Kebriaei P, Dabaja B, Shpall EJ, Neelapu S, Wierda W, Ravandi F, Kantarjian H. (P413) BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) AS CONSOLIDATION TREATMENT IN ADULTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH MARROW BLASTS <5%, INCLUDING PATIENTS (PTS) WITH NGS MRD NEGATIVE DISEASE. HemaSphere 8(S1):644-645, 2024. PMID: None.
Garciaz S, Bajel A, Maiti A, Desai P, Huls G, Boissel N, Jongen-Lavrencic M, Mantzaris I, Botton SD, Leeuw DD, Fleming S, Saultz J, Jensen K, Timothy, Wagenaar, Marpadga R, Yang Y, Ziti-Ljajic S, Virone-Oddos A, Meloni M, Nicolazzi C, Draganov D, Abbadessa G, Cooley S, Stein A. (S146) COMPLETED DOSE ESCALATION FROM THE FIRST-IN-HUMAN, PHASE 1/2 STUDY OF CD123 NK CELL ENGAGER, SAR443579, IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR HIGH RISK-MYELODYSPLASIA. HemaSphere 8(S1):101-102, 2024. PMID: None.
Takeda S, Lo P, Schefer D, Siddiqui M, Tyagi A, Battula VL, Maiti A, Tavazoie S, Tavazoie M, Darst DM, Kurth I. Abstract B122: 2 for 1: Targeting tumor-associated macrophages and cancer cells with a novel MERTK-targeting antibody-drug conjugate (ADC). Molecular Cancer Therapeutics 22(12_Supplement):B122-B122, 2023. PMID: None.
Bazinet A, Kantarjian HM, Ravandi F, Short NJ, Daver N, Ohanian M, Yilmaz M, Chien KS, Maiti A, DiNardo CD, Ishizawa J, Masarova L, Bull-Linderman D, Borthakur G, Jabbour E, Garcia-Manero G, Kadia TM. Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study. Blood 142(Supplement 1):2909, 2023. PMID: None.
Senapati J, Loghavi S, Reville PK, Daver N, Borthakur G, DiNardo CD, Jabbour E, Short NJ, Pemmaraju N, Maiti A, Issa GC, Popat UR, Alousi A, Shpall EJ, Sasaki K, Garcia-Manero G, Ravandi F, Kadia TM. Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis. Blood 142(Supplement 1):4282, 2023. PMID: None.
Atluri H, Mullin J, Takahashi K, Loghavi S, Maiti A, Sasaki K, Daver N, Valero YA, Pemmaraju N, Borthakur G, Hammond DE, Chien KS, Ferrajoli A, Short NJ, Abbas HA, Jabbour E, Andreeff M, Ravandi F, Tidwell RS, Wang X, Konopleva MY, Garcia-Manero G, Kantarjian HM, DiNardo CD. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update. Blood 142(s):968, 2023. PMID: None.
Post SM, Rodriguez AG, Benitez O, Brottem J, Wang I, Chang J, Frattini MG, Maiti A. Unraveling Novel Mechanisms for Targeting the Intra-S-Phase Checkpoint in p53-Mutated Acute Myeloid Leukemia. Blood 142(Supplement 1):1423, 2023. PMID: None.
Nishida Y, Ayoub E, Scruggs D, Khazaei S, Munir F, Ostermann LB, Mak PY, Baozhen K, Carter BZ, Baran N, Maiti A, Mohanty V, Chen K, Navin N, Haferlach T, Ren Z, Tong Y, Chen D, Issa GC, Andreeff M. Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC. Blood 142(Supplement 1):583, 2023. PMID: None.
Arani N, Almanza E, Bataller A, DiNardo CD, Ravandi F, Daver N, Pemmaraju N, Yilmaz M, Maiti A, Reville PK, Loghavi S, Abbas HA, Garcia-Manero G, Short NJ, Kantarjian HM, Kadia TM. Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens. Blood 142(s):4236, 2023. PMID: None.
Maiti A, Muftuoglu M, Ignatz-Hoover JJ, DiNardo CD, Ravandi F, Andreeff M, Xiao L, Huang X, Patel KP, Litten JB, Bourk E, Astrow S, Kantarjian HM, Tomlinson BK, Daver N, Wald D. Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial. Blood 142(Supplement 1):4863, 2023. PMID: None.
Bajel A, Garciaz S, Desai P, Huls GA, Maiti A, Jongen-Lavrencic M, Boissel N, Botton SD, de Leeuw DC, Fleming S, Zwaan C, Arellano M, Avigan D, Saultz JN, Mantzaris I, Jensen K, Wagenaar T, Mi G, Ziti-Ljajic S, Draganov D, Abbadessa G, Stein AS. First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics. Blood 142(s):3474, 2023. PMID: None.
Bazinet A, Garcia-Manero G, Short NJ, Valero YA, Abuasab T, Islam MR, Montalbano K, Issa GC, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau SM, Jabbour E, Montalban-Bravo G, Pierce S, DiNardo CD, Kadia TM, Daver N, Konopleva MY, Kantarjian HM, Ravandi F. A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia. Blood 142(s):833, 2023. PMID: None.
Kim YJ, Li Z, Maiti A, Tanaka T, Uryu H, Furudate K, Hayes K, Daver N, Pemmaraju N, Kadia TM, Ravandi F, Short NJ, Ohanian M, Borthakur G, Jain N, Issa GC, Masarova L, Kornblau SM, Wierda WG, Loghavi S, Wang SA, Garcia-Manero G, Kantarjian H, DiNardo CD, Konopleva MY, Takahashi K. Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms. Blood 142(s):2931, 2023. PMID: None.
Gener-Ricos G, Borthakur G, Sasaki K, Tang G, Montalban-Bravo G, Jabbour E, Ohanian M, Yilmaz M, Haddad FG, Chien KS, Ishizawa J, Short NJ, Maiti A, Swaminathan M, Garcia-Manero G, Daver N, DiNardo CD, Ravandi F, Kadia TM. Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results. Blood 142(s):2903, 2023. PMID: None.
Almanza E, Bataller A, Garcia-Manero G, Maiti A, Montalban-Bravo G, Takahashi K, Short NJ, Jabbour E, Ravandi F, Valero YA, Kadia TM. Fludarabine, Cytarabine (ARA-C) and Pegylated Erwinase (PEGCRISANTASPASE) in Patients with Relapsed or Refractory Leukemia. Blood 142(Supplement 1):5971, 2023. PMID: None.
Nguyen D, Ravandi F, Wang SA, Jorgensen JL, Wang W, Chien KS, Montalban-Bravo G, Issa GC, Maiti A, Valero YA, Daver N, DiNardo CD, Jabbour E, Kadia TM, Pemmaraju N, Yilmaz M, Lee J, Bachireddy P, Popat UR, Garcia-Manero G, Kantarjian HM, Short NJ. A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML. Blood 142(Supplement 1):None, 2023. PMID: None.
Khasawneh A, Paran FJ, Oyama R, Maiti A, Abbas HA, Wang B, Desai PN, Hayes K, Harman JR, Su X, DiNardo CD, Andreeff M, Milne TA, Konopleva MY, Tabe Y. Molecular Profiling of Response and Resistance to Venetoclax-Decitabine Therapy in Acute Myeloid Leukemia. Blood 142(Supplement 1):4159, 2023. PMID: None.
Kadia TM, Kantarjian H, Alatrash G, Sergeeva A, He H, John LS, Koppikar P, Kerros C, Clise-Dwyer K, Ruissard K, Maiti A, DiNardo CD, Jabbour E, Verstovsek S, Pemmaraju N, Jain N, Issa GC, Garcia-Manero G, Montalban-Bravo G, Shastri A, Couriel DR, Pinsoy MR, Parshottham S, Champlin RE, Cortes J, Molldrem JJ. Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies. Blood 142(Supplement 1):1545, 2023. PMID: None.
Yilmaz M, Muftuoglu M, DiNardo CD, Kadia TM, Konopleva MY, Borthakur G, Pemmaraju N, Short NJ, Valero YA, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike A, Loghavi S, Patel KP, Tang G, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Ravandi F, Andreeff M, Daver N. Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML. Blood 142(s):158, 2023. PMID: None.
Bataller A, Kantarjian HM, Kadia TM, Daver N, DiNardo CD, Borthakur G, Short NJ, Yilmaz M, Issa GC, Valero YA, Montalban-Bravo G, Maiti A, Abbas HA, Jabbour E, Wierda WG, Garcia-Manero G, Ravandi F. Mutational and Cytogenetic Dynamics at Diagnosis and Relapse in Acute Myeloid Leukemia: Influence of Intensity and Type of Treatment. Blood 142(s):723, 2023. PMID: None.
Sango J, Carcamo S, Cruz-Rodriguez N, Sirenko M, Maiti A, Olszewska M, Wang T, Ulukaya GB, Tomalin L, Olivier E, Jaud M, Chaligne R, Mansour H, Demircioglu D, Landau DA, Papaemmanuil E, DiNardo CD, Hasson D, Konopleva MY, Papapetrou E. N/KRAS -Mutant AML LSCs Originate from Committed Myelomonocytic Progenitors and Drive Clinical Resistance to Venetoclax. Blood 142(Supplement 1):403, 2023. PMID: None.
Montalban-Bravo G, Short NJ, Chien KS, Valero YA, Daver N, Borthakur G, Swaminathan M, Maiti A, Hammond DE, Nogueras-Gonzalez G, Huang X, Schneider H, Shelly K, Kadia TM, Kantarjian HM, Garcia-Manero G. Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes. Blood 142(Supplement 1):1876, 2023. PMID: None.
Wieduwild E, Floch AL, Garulli C, Imbert C, Gassart AD, Brune P, Lemmens K, Garciaz S, Maiti A, Peterlin P, Leparquier C, Iche M, Vey N, Olive D, Frohna P. Evaluation of ICT01, a γ9δ2 T Cell-Activating Monoclonal Antibody, Combined with Venetoclax and Azacitidine in 1L AML (EVICTION Study). Blood 142(Supplement 1):1552, 2023. PMID: None.
Huante EA, Bataller A, Hammond DE, Chien KS, DiNardo CD, Short NJ, Maiti A, Montalban-Bravo G, Ravandi F, Garcia-Manero G, Kadia TM. Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML). Blood 142(s):2922, 2023. PMID: None.
Maiti A, DiNardo CD, Ohanian M, Daver N, Borthakur G, Chien KS, Issa GC, Takahashi K, Masarova L, Valero YA, Jabbour E, Wierda WG, Short NJ, MacFarland M, Pike A, Kadia TM, Ravandi F, Kantarjian HM, Garcia-Manero G, Konopleva MY. Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia. Blood 142(s):4289, 2023. PMID: None.
Maiti A, Daver N, Iyer SP, McCall D, Gohil SH, Jimenez JL, Lane H, Kim B, Dao K, Patou G, Panicker S, Covert K, Parry GC, Allen CE. A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis. Blood 142(Supplement 1):1162, 2023. PMID: None.
Bataller A, Kantarjian HM, Kadia TM, Daver N, DiNardo CD, Borthakur G, Short NJ, Yilmaz M, Issa GC, Valero YA, Montalban-Bravo G, Maiti A, Abbas HA, Jabbour E, Wierda WG, Garcia-Manero G, Ravandi F. Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment. Blood 142(s):1480, 2023. PMID: None.
Arora S, Senapati J, Pemmaraju N, Bose P, Masarova L, Montalban-Bravo G, Maiti A, Kadia TM, Jabbour E, Garcia-Manero G, Kantarjian HM, Daver N. Five-Year Follow up Results of Phase II Clinical Trial Evaluating Ruxolitinib (RUX) and Azacitidine (AZA) Combination Therapy in Patients (pts) with Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). Blood 142(s):1861, 2023. PMID: None.
Nguyen D, Kantarjian HM, Short NJ, Jain N, Haddad FG, Yilmaz M, Ferrajoli A, Kadia TM, Valero YA, Maiti A, Nasnas C, Nasr L, Garris R, Konopleva MY, Ravandi F, Jabbour E. Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia. Blood 142(Supplement 1):4245, 2023. PMID: None.
Yamatani K, Watanabe T, Saito K, Maiti A, Yamashita S, Khasawneh A, Paran FJ, Hayes K, Borthakur G, Harman JR, Kimura S, DiNardo CD, Milne TA, Andreeff M, Tabe Y, Konopleva MY. PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia. Blood 142(Supplement 1):4162, 2023. PMID: None.
Senapati J, Kantarjian HM, Jabbour E, Babakhanlou R, Kadia TM, Borthakur G, Konopleva MY, Wierda WG, Burger JA, Issa GC, Maiti A, Balkin HS, Kelly M, Garris R, Ferrajoli A, Garcia-Manero G, Valero YA, Kebriaei P, Short NJ, Jain N, Ravandi F. Nelarabine (NEL), Pegylated Asparginase (PEG) and Venetoclax (VEN) Incorporated to HCVAD Chemotherapy in the Frontline Treatment of Adult Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL). Blood 142(s):963, 2023. e-Pub 2023. PMID: None.
Konopleva MY, Bhatt VR, Mantzaris I, Maiti A, Gundabolu K, Jensen K, Schafer J, Mi G, Drewniak A, Krenz H, Saleem R, Abbadessa G, Daver N. A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). Blood 142(S):5972, 2023. PMID: None.
Tyagi A, Siddiqui M, Kurth I, Takeda S, Eckstrom A, Borgman J, Maiti A, Battula VL. Targeting Myeloid Epithelial Tyrosine Kinase (MERTK) Receptor in Acute Myeloid Leukemia Using a Novel Antibody Drug Conjugate, Rgx-019-MMAE. Blood 142(Supplement 1):5955, 2023. PMID: None.
Jongen-Lavrencic M, Bajel A, Garciaz S, Maiti A, Fleming S, Button S, Huls GA, Jensen K, Ziti-Ljajic S, Draganov D, Rotolo F, Palu C, Courta J, Passe-Coutrin W, Traudtner K, Wagenaar T, Abbadessa G, Stein A. 823O Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute myeloid leukemia (R/R AML), B cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS). Annals of Oncology 34(2):S543-S544, 2023. e-Pub 2023. PMID: None.
Short N, Macaron W, Dinardo C, Daver N, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa G, Sasaki K, Burger J, Maiti A, Alvarado Y, Thankachan J, Abranova R, Nasr L, Nasnas C, Zoghbi M, Kadia T, Konopleva M, Kantarjian HM, Ravandi F. P485 AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3- MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY. HemaSphere 2023(7(S3)):816-817, 2023. PMID: None.
Nguyen D, Kantarjian HM, Bidikian A, Dinardo C, Kadia T, Daver N, Borthakur G, Jabbour E, Yilmaz M, Short N, Maiti A, Sasaki K, Montalban-Bravo G, Hammond D, Pierce S, Andreeff M, Garcia-Manero G, Ravandi F, Issa G. P535 OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND. HemaSphere 2023(7 (S3)):923-924, 2023. PMID: None.
Short NJ, Bachireddy P, Huang X, Hwang H, Leng X, Lee J, Nguyen D, Garcia-Manero G, Dinardo CD, Borthakur G, Kadia TM, Daver NG, Issa GC, Maiti A, Ravandi F. A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure. J Clin Oncol 41(22023 (S16)), 2023. PMID: None.
Takeda S, Lo PC, Schefer D, Andreu-Agullo C, Battula VL, Maiti A, Tavazoie M, Darst DM, Kurth I. RGX-019-MMAE, a novel MERTK-targeting antibody-drug conjugate (ADC) with robust anti-tumor efficacy in both solid and liquid tumors. J Clin Oncol 41(2023 (S 16)), 2023. PMID: None.
Senapati J, Ravandi F, Dinardo CD, Issa GC, Sasaki K, Konopleva M, Macaron W, Nasr L, Zoghbi M, Nasnas CC, Pemmaraju N, CHien K, Ohanian M, Jabbour E, Maiti A, Kantarjian HM, Short NJ. A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML). J Clin Oncol 2023(41 (S16)), 2023. PMID: None.
Short NJ, Jabbour E, Jain N, Haddad F, Macaron W, Yilmaz M, Ferrajoli A, Kadia TM, Alvarado Valero Y, Maiti A, Nasr LF, Zoghbi M, Nasnas C, Garris R, Zhao M, Konopleva M, Ravandi F, Kantarjian HM. A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL). J Clin Oncol 2023(41 (S16)), 2023. PMID: None.
Stein A, Jongen-Lavrencic M, Garciaz S, Huls G, Maiti A, Boissel N, De Botton S, Fleming S, Zwaan CM, de Leeuw DC, Desai P, Arellano M, Avigan D, Langemeijer S, Jensen KA, Wagenaar T, Mi G, Abbadessa G, Bajel A. A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia. J Clin Oncol 41(2023 (S 16)), 2023. PMID: None.
Stein AS, Jongen-Lavrencic M, Garciaz S, Huls GA, Maiti A, Boissel N, De Botton S, Fleming S, Zwaan CM, De Leeuw DC, Desai P, Arellano MA, Avigan D, Langeijer S, Jensen K, Wagenaar T, Mi G, Abbadessa G, Bajel A. P494 A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIA. HemaSphere 2023(7 (S3)):836-837, 2023. PMID: None.
Short N, Jabbour N, Jain N, Haddad F, Yilmaz M, Nasr L, Ferrajoli A, Kadia T, Alvarado Y, Maiti A, Macaron W, Zoghbi M, Nasnas C, Garris R, Zhao M, Konopleva M, Ravandi F, Kantarjian H. P358 HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY. HemaSphere 2023(7 (S3)):553, 2023. PMID: None.
Bose P, Masarova L, Pemmaraju N, Dobbins M, Jain N, Abbas H, Kornblau S, |Maiti A, Veletic I, Manshouri T, Beldsoe S, Richie M, Hall-Moore N, Zhou L, Wang X, Kantarjian HM, Estrov Z, Verstovsek S. P1025 A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS. HemaSphere 2023(7 (S3)):1954-1955, 2023. PMID: None.
Senapati J, Ravandi F, Dinardo CD, Issa GC, Sasaki K, Konopleva M, Macaron W, Nasr LF, Zoghbi M, Nasnas CC, Pemmaraju N, Chien KS, Ohanian M, Jabbour E, Maiti A, Kantarjian HM, James Short AN. A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML). Journal of Clinical Oncology 41(16):e19044, 2023. PMID: None.
Short NJ, Jabbour E, Jain N, Haddad F, Macaron W, Yilmaz M, Ferrajoli A, Kadia TM, Valero YA, Maiti A, Nasr LF, Zoghbi M, Nasnas CC, Garris R, Zhao M, Konopleva M, Ravandi F, M Kantarjian AH. A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL). None 41(16):e19017, 2023. PMID: None.
Short NJ, Bachireddy P, Huang X, Hwang H, Leng X, Lee J, Nguyen D, Garcia-Manero G, Dinardo CD, Borthakur G, Kadia TM, Daver NG, Issa GC, Maiti A, Ravandi AF. A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure. Journal of Clinical Oncology 41(16):TPS7076, 2023. PMID: None.
Takeda S, Lo P, Schefer D, Andreu-Agullo C, Battula VL, Maiti A, Tavazoie M, Darst DM, Kurth AI. RGX-019-MMAE, a novel MERTK-targeting antibody-drug conjugate (ADC) with robust anti-tumor efficacy in both solid and liquid tumors. Journal of Clinical Oncology 41(16):e15103, 2023. PMID: None.
Stein AS, Jongen-Lavrencic M, Garciaz S, Huls GA, Maiti A, Boissel N, Botton SD, Fleming S, Zwaan C, de Leeuw DC, Desai P, Arellano ML, Avigan D, Langemeijer S, Jensen KA, Wagenaar T, Mi G, Abbadessa G, Bajel AA. A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia. Journal of Clinical Oncology 41(16):7005, 2023. PMID: None.
Altman JK, Abaza Y, Keng M, Maiti A, Koprivnikar J, Tessler S, Blumberg C, Flaishon L, Yakar RB. Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study. Blood 142(Supplement 1):5970, 2023. PMID: None.
Sango J, Carcamo S, Cruz-Rodriguez N, Sirenko M, Maiti A, Olszewska M, Wang T, Ulukaya GB, Tomalin L, Olivier E, Jaud M, Chaligne R, Mansour H, Demircioglu D, Landau DA, Papaemmanuil E, DiNardo CD, Hasson D, Konopleva MY, Papapetrou E. N/KRAS-Mutant AML LSCs Originate from Committed Myelomonocytic Progenitors and Drive Clinical Resistance to Venetoclax. Blood 142(None):403, 2023. PMID: None.
Kadia T, Kantarjian H, Alatrash G, Sergeeva A, He H, John LS, Koppikar P, Kerros C, Clise-Dwyer K, Ruissard K, Maiti A, DiNardo CD, Jabbour E, Verstovsek S, Pemmaraju N, Jain N, Issa GC, Garcia-Manero G, Montalban-Bravo G, et al. Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies. Blood 142(None):1545, 2023. PMID: None.
Nguyen D, Ravandi F, Wang SA, Jorgensen JL, Wang W, Chien KS, Montalban-Bravo G, Issa GC, Maiti A, Valero YA, Daver N, DiNardo CD, Jabbour E, Kadia TM, Pemmaraju N, Yilmaz M, Lee J, Bachireddy P, Popat UR, et al. A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive. Blood 142(None):322, 2023. PMID: None.
Kim YJ, Li Z, Maiti A, Tanaka T, Uryu H, Furudate K, Hayes K, Daver N, Pemmaraju N, Kadia TM, Ravandi F, Short N, Ohanian M, Borthakur G, Jain N, CIssa G, Masarova L, Kornblau SM, Wierda W, et al. Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms. Blood 142(None):2931, 2023. PMID: None.
Bataller A, Kantarjian HM, Kadia TM, Daver N, DiNardo CD, Borthakur G, Short NJ, Yilmaz M, Issa GC, Valero YA, Montalban-Bravo G, Maiti A, Abbas HA, Jabbour E, Wierda WG, Garcia-Manero G, Ravandi AF. Mutational and Cytogenetic Dynamics at Diagnosis and Relapse in Acute Myeloid Leukemia: Influence of Intensity and Type of Treatment. Blood 142(None):723, 2023. PMID: None.
Dalessandri T, Zarif MN, Maiti A, Daver N, Maltais A. Feeder-free expansion of autologous cytotoxic NK cells for acute myeloid leukemia treatment. Journal of Immunotherapy of Cancer 11(Suppl 1):339, 2023. PMID: None.
Atluri H, Mullin J, Takahashi K, Loghavi S, Maiti A, Sasaki K, Daver N, Valero YA, Pemmaraju N, Borthakur G, Hammond DE, Chien KS, Ferrajoli A, Short NJ, Abbas HA, Jabbour E, Andreeff M, Ravandi F, Tidwell RS, et al. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib:. Blood 142(None):968, 2023. PMID: None.
Yamatani K, Maiti A, Watanabe T, Saito K, Hayes K, Kinjo S, Ikeo K, Miida T, Kimura S, DiNardo CD, Su X, Tabe Y, Konopleva MY. Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses. Blood 140(1):3097-3098, 2022. e-Pub 2022. PMID: None.
Desikan SP, Kantarjian HM, Jabbour E, Chien KS, Montalban-Bravo G, Alvarado Y, Borthakur G, Issa GC, Daver N, Pemmaraju N, Yilmaz M, Hammond D, Maiti A, DiNardo CD, Ravandi F, Garcia-Manero G, Kadia TM. Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials. Blood 140(Supplement 1):3301-3303, 2022. PMID: None.
Reville P, Kantarjian HM, Borthakur G, Pemmaraju N, Daver N, DiNardo CD, Sasaki K, Short N, Issa G, Ohanian M, Jabbour E, Montalban-Bravo G, Maiti A, Jain N, Ferrajoli A, Bhalla KN, Takahashi K, Rausch CR, Hammond D, Malla R, Quagliato K, Brandt M, Popat UR, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM. Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study. Blood 140(Supplement 1):9041-9043, 2022. PMID: None.
Gener-Ricos G, Sasaki K, Loghavi S, Maiti A, Short NJ, Haddad F, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel KP, Andreeff M, DiNardo CD. A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies. Blood 140(Supplement 1):11830-11832, 2022. PMID: None.
Short N, DiNardo CD, Daver N, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Sasaki K, Thompson PA, Burger JA, Maiti A, Alvarado Y, Kwari M, Delumpa R, Thankachan J, Mayor E, Loiselle C, Milton A, Banks G, Kadia TM, Konopleva M, Kantarjian H, Ravandi F. Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia. Blood 140(S):2007-2009, 2022. PMID: None.
Senapati J, Short NJ, Maiti A, Abbas H, Daver N, Pemmaraju N, Pierce SA, Chien KS, Sasaki K, Hammond D, Borthakur G, Ravandi F, Kantarjian HM, DiNardo C. Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia. Blood 140(Supplement 1):1427-1429, 2022. PMID: None.
Daver N, Jayastu J, Maiti A, Loghavi S, Kadia TM, DiNardo CD, Pemmaraju N, Jabbour E, Montalban-Bravo G, Tang G, Sasaki K, Borthakur B, Yilmaz M, Alvarez J, Pierce SA, Nogueras GM, González, Ning J, Issa GC, Andreeff M, Abbas H, Ravandi F, Garcia-Manero G, Kantarjian HM. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood 140(Supplement 1):141-144, 2022. PMID: None.
Maiti A, DiNardo CD, Ohanian M, Pemmaraju N, Daver N, Borthakur G, Ravandi F, Issa GC, Garcia-Manero G, Jain N, Kadia TM, Masarova L, Wierda WG, Yilmaz M, Alvarado Y, Jabbour E, Short NJ, Takahashi K, Loghavi S, Patel KP, Montalbano K, Pierce SA, Bivins CA, Mehta RS, Alatrash G, Popat UR, Kebriaei P, Oran B, Shpall EJ, Champlin RE, Kantarjian HM, Konopleva MY. Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial. Blood 140(Supplement 1):7725-7728, 2022. PMID: None.
Desikan S, Konopleva MY, Takahashi K, Lachowiez CA, Loghavi S, Xiao L, Kadia TM, Daver N, Short NJ, Sasaki K, Borthakur G, Issa GC, Maiti A, Chien KS, Alvarado Y, Montalban-Bravo G, Masarova L, Yilmaz M, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau SM, Ravandi F, Kantarjian HM, DiNardo C. Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia. Blood 140(Supplement 1):534-536, 2022. e-Pub 2022. PMID: None.
Huante EA, Kantarjian HM, Chien K, DiNardo CD, Short N, Maiti A, Montalban-Bravo G, Daver N, Kawedia JD, Bowie K, Pierce SA, Ravandi F, Konopleva M, Garcia-Manero G, Kadia TM. Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML). Blood 140(Supplement 1):3344-3346, 2022. PMID: None.
Babakhanlou R, Kantarjian HM, Jabbour E, Borthakur G, Konopleva MY, Wierda WG, Burger JA, Issa GC, Maiti A, Balkin H, Kelly M, Garris R, Ferrajoli A, Garcia-Manero G, Alvarado Y, Short NJ, Jain N, Ravandi F. Incorporation of Nelarabine (NEL), Pegylated Asparaginase (PEG) and Venetoclax (VEN) in the Frontline Therapy of Adult Patients with T-Acute Lymphoblastic Leukemia/T-Lymphoblastic Lymphoma (T-ALL/LBL). Blood 140(Supplement 1):11671-11673, 2022. e-Pub 2022. PMID: None.
Nishida Y, Scruggs DA, Ayoub E, Patsilevas T, Ruvolo V, Mak PY, Carter BZ, Boettcher S, Maiti A, Zhou Q, Yang Z, Yan H, Ma L, Andreeff M. C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53 -Independent Cell Death in Acute Myeloid Leukemia and Lymphomas. Blood 140(Supplement 1):483-484, 2022. PMID: None.
Bazinet A, Kadia TM, Short NJ, Borthakur G, Wang SA, Loghavi S, Jorgensen JL, Patel KP, DiNardo CD, Daver N, Alvarado Y, Haddad F, Pierce SA, Nogueras-González GM, Maiti A, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian HM, Ravandi F. Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia. Blood 140(Supplement 1):2267-2269, 2022. e-Pub 2022. PMID: None.
Abuasab T, Garcia-Manero G, Short NJ, Alvarado Y, Issa GC, Islam R, A M, Yilmaz M, Jain N, Masarova L, Kornblau SM, Jabbour E, Pemmaraju N, Montalban-Bravo G, Pierce SA, DiNardo CD, Kadia TM, Daver N, Konopleva MY, Kantarjian HM, Ravandi F. Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy. Blood 140(Supplement 1):3324-3326, 2022. PMID: None.
Stein AS, Bajel A, Fleming S, Jongen-Lavrencic M, Garciaz S, Maiti A, Boissel N, De Botton S, Huls GA, de Leeuw DC, Avigan D, Jensen K, Demers B, Wagenaar T, Mi G, Ziti-Ljajic S, Draganov D, Abbadessa G, Wei AH. An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS). Blood 140(Supplement 1):7476-7477, 2022. PMID: None.
Senapati J, Ravandi F, DiNardo CD, Issa GC, Sasaki K, Konopleva MY, Pemmaraju N, Chien KS, Ohanian M, Jabbour E, Maiti A, Roy E, Delumpa R, Rivera J, Loiselle C, Banks G, Kantarjian HM, Short NJ. A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML). Blood 140(Supplement 1):3880-3882, 2022. PMID: None.
Nishida Y, Scruggs DA, Ayoub E, Patsilevas T, Ruvolo V, Mak PY, Carter BZ, Steffen Boettcher S, Maiti A, Zhou Q, Yang Z, Yan H, Ma L, Andreeff M. C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas. Blood 140(1):483-484, 2022. e-Pub 2022. PMID: None.
Short NJ, DiNardo C, Daver N, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Sasaki K, Thompson P, Burger JA, A M, Alvarado Y, Kwari M, Delumpa R, Thankachan J, Mayor E, Loiselle C, Milton A, Banks G, Kadia T, Konopleva M, Kantarjian H, Ravandi F. Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia. Blood 140(1):2007-2009, 2022. PMID: None.
Atluri H, Maiti A, Sasaki K, Daver N, Alvarado Y, Hossain F, Wang X, Pemmaraju N, Takahashi K, Borthakur G, Ferrajoli A, Short NJ, Abbas H, Ravandi F, Jabbour E, Andreeff M, Garcia-Manero G, Kantarjian HM, Konopleva MY, DiNardo C. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia. Blood 140 (Supplement 1)(Supplement 1):6170-6172, 2022. PMID: None.
Macaron W, Ravandi F, Kadia TM, DiNardo CD, Issa GC, Daver N, Wang SA, Jorgensen JL, Patel K, Loghavi S, Konopleva MY, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall EJ, Popat UR, Alatrash G, Pierce SA, Kantarjian HM, Short NJ. Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission. Blood 140(Supplement 1):543-545, 2022. e-Pub 2022. PMID: None.
Desikan SP, Daver N, Loghav S, Kadia TM, Short NJ, DiNardo CD, Borthakur G, Pierce SA, Patel KP, Abbas HA, Maiti A, Garcia-Manero G, Ravandi F, Kantarjian HM, Yilmaz M. Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens. Blood 140(1):11788-11790, 2022. e-Pub 2022. PMID: None.
Nishida, Y, Scruggs, DA, Ayoub, E, Patsilevas, T, Ruvolo, VR, Mak, PY, Carter, BZ, Boettcher, S, Maiti, A, Zhou, Q, Yang, Z, Yan, H, Ma, L, Andreeff, M. AML-147 C-MYC Targeting by Degradation. Clinical Lymphoma, Myeloma and Leukemia 22:S218, 2022. PMID: 36163775.
Yilmaz M, Muftuoglu M, Kantarjian HM, Dinardo CD, Kadia TM, Konopleva M, Borthakur G, Pemmaraju N, Short NJ, Valero YA, Maiti A, Masarova L, Bravo GM, Loghavi S, Kornblau SM, Jabbour E, Garcia-Manero G, Ravandi F, Andreeff M, Guastad Daver AN. Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial. Journal of Clinical Oncology 40(16):7036, 2022. PMID: None.
Lachowiez CA, Garcia JS, Borthakur G, Loghavi S, Zeng Z, Tippett GD, Kadia TM, Masarova L, Yilmaz M, Maiti A, Bose P, Takahashi K, Jabbour E, Ravandi F, Daver NG, Garcia-Manero G, Vyas P, Kantarjian HM, Konopleva M, Denton Dinardo AC. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies. Journal of Clinical Oncology 40(16):7018, 2022. PMID: None.
Venugopal S, Jabbour E, Pemmaraju N, Montalban-Bravo G, Chien KS, Daver NG, Jain N, Burger JA, Valero YA, Maiti A, Dinardo CD, Borthakur G, Malla R, Garcia-Manero G, Ravandi F, Kantarjian HM, M Kadia AT. Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials. Journal of Clinical Oncology 40(16):e19028, 2022. PMID: None.
Ong F, Ravandi F, Popat UR, Kadia TM, Daver NG, Dinardo CD, Konopleva M, Borthakur G, Shpall EJ, Oran B, Alatrash G, Mehta RS, Jabbour E, Yilmaz M, Issa GC, Garcia-Manero G, Maiti A, Abbas H, Champlin RE, James Short AN. Impact of induction approach on post-stem cell transplant (SCT) outcomes in older adults with newly diagnosed acute myeloid leukemia (AML). Journal of Clinical Oncology 40(16):7038, 2022. PMID: None.
Venugopal S, kantarjian H, Maiti A, Short N, Montalban-Bravo G, Alvarado Y, Chien KS, Rashmi, Kanagal-Shamanna, Pemmaraju N, Daver N, Kadia T, Borthakur G, Jabbour E, Garcia-Manero G. P784 A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML). HemaSphere 6(S3):1298-1299, 2022. PMID: None.
Ong F, Ravandi F, Popat U, Kadia TM, Daver N, DiNardo C, Konopleva M, Borthakur G, Elizabeth J, Shpall, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Garcia-Manero G, Maiti A, Abbas HA, Champlin RE, Short NJ. P566 IMPACT OF FRONTLINE INDUCTION APPROACH ON POST-STEM CELL TRANSPLANT (SCT) OUTCOMES IN OLDER ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML). HemaSphere 6(S3):896-897, 2022. PMID: None.
Ravandi F, Jabbour E, Jain N, Kadia T, Gautam B, Konopleva M, Wierda W, Burger J, Issa G, Maiti A, Balkin H, Kelly M, Garris R, Kebriaei P, Ferrajoli A, Garcia-Manero G, Alvarado Y, Short N, Kantarjian H. P365 INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T- LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL). HemaSphere 6(s3):525-526, 2022. PMID: None.
Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo C, Kadia T, Borthakur G, Pemmaraju N, Short N, Alvarado Y, Maiti A, Masarova L, Bravo GM, Loghavi S, Patel K, Kornblau S, Jabbour E, Garcia-Manero G, Andreeff M, Daver N. S127 QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY. HemaSphere 6(S3):55-56, 2022. PMID: None.
Venugopal S, Jabbour E, Pemmaraju N, Montalban-Bravo G, Chien KS, Daver N, Jain N, Burger J, Yesid, Alvarado, Maiti A, DiNardo CD, Borthakur G, Malla R, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia T. P581 PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS. HemaSphere 6(S3):926-927, 2022. PMID: None.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour E, Daver N, Borthakur G, Garcia Manero G, Pierce S, Montalbano K, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau S, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson P, Rausch C, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. What to use to treat AML: the role of emerging therapies. Hematology, ASH Education Program 2021(1), 2021. PMID: None.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia T, Jabbour E, Daver N Borthakur G, Garcia-Manero G, Pierce S, Montalbano K, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau S, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson P, Rauch C, Ning J, Kantarjian HM, DiNardo C, Konopleva MY. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Advances 5(24):5565-73, 2021. PMID: None.
Lachowiez C, DiNardo CD, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa GC, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva M, Kantarjian HM. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Blood(138 (Supplement 1)):701, 2021. PMID: None.
Yilmaz M, Muftuoglu M, Kantarjian HM, DiNardo CD, Kadia TM, Konopleva MY, Borthakur G, Pemmaraju N, Short NJ, Alvarado Y, Maiti A, Masarova L, Montalban Bravo G, Jurisprudencia C, Pike A, Loghavi S, Patel K, Tang G, Matthews J, Kornblau S, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. Blood 2021(138 (Supplement 1)):370, 2021. PMID: None.
Short N, Montalban-Bravo G, Alvarado Y, Konopleva M, Jabbour E, Garcia-Manero G, Yilmaz M, Jain N, Borthakur G, Dinardo C, Daver N, Issa G, Ohanian M, Pemmaraju N, Sasaki K, Maiti A, Chien K, Ravandi F, Andreeff M, Bose P, Delumpa R, Pierce S, Waller L, Banks G, Kantarjian H, Cortes J. Azacitidine, venetoclax and pevonedistat as frontline therapy for patients with secondary acute myeloid leukemia who are unfit for intensive chemotherapy: results from a phase I/II study. Blood(138):2349, 2021. PMID: None.
Lacher M, Richardson M, Schaffert S, Kita R, Santaguida M, Anderson E, Roselli J, Anderson W, Paul A, Gu C, Vanderlaag K, Zeng Z, Maiti A, DiNardo CD, Konopleva MY. Prediction of Clinical Response to Venetoclax Plus Decitabine in AML Using a 7-Day Ex Vivo Assay. Blood(138 (Supplement 1)):3464, 2021. PMID: None.
Maiti A, DiNardo CD, Rausch C, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver N, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Jabbour E, Short NJ, Montalban Bravo G, Jain N, Kornblau S, Masarova L, Wierda W, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov Z, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson P, Montalbano K, Vaughan K, Bivins C, Pierce S, Qiao W, Ning J, Welch J, Kantarjian HM, Konopleva MY. Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Blood(138 (Supplement 1)):694, 2021. PMID: None.
Siddiqui M, Maiti A, Daver N, Kadia T, Rausch C, Alvarado Y, Ohanian M, Short N, Takahashi K, Yilmaz M, Ravandi F, Kantarjian H, DiNardo C, Konopleva M. AML-310: Prognostic Value of CRh in Acute Myeloid Leukemia Treated with Venetoclax and Decitabine. Clinical Lymphoma Myeloma and Leukemia 2021(21):S303-S304, 2021. PMID: None.
Yilmaz M, Kantarjian H, Muftuoglu M, Dinardo CD, Kadia TM, Konopleva MY, Borthakur G, Pemmaraju N, Short NJ, Alvarado Y, Maiti A, Montalban-Bravo G, Jurisprudencia C, Pike A, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. EP430 Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML). J Clin Oncol 39(15):e19019-e19019, 2021. PMID: None.
Venugopal S, Loghavi S, DiNardo CD, Konopleva MY, Kadia T, Bhalla K, Issa GC, Ravandi F, Daver N, Borthakur G, E Jabbour J, Montalban-Bravo G, Yilmaz M, Chien K, Maiti A, Kantarjian HM, Short NJ. S132 RUNX1 MUTATIONS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA DO NOT ADVERSELY IMPACT CLINICAL OUTCOMES IN THE MODERN ERA. EHA2021 Virtual Congress, 2021. PMID: None.
Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver N, Kadia T, Rausch C, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma 62(14):3501-5, 2021. PMID: None.
Saxena K, Jabbour E, Issa GC, Sasaki K, Maiti A, Ravandi F, Daver N, Kadia T, DiNardo C, Konopleva M, Chien K, Pierce S, Kantarjian H, Short N. EP676 FRONTLINE TREATMENT APPROACHES FOR CML IN MYELOID BLAST PHASE: A SINGLE-CENTER EXPERIENCE OVER 2 DECADES. J Hematol Oncol 2021(14):94, 2021. PMID: None.
Maiti A, DiNardo C, Qiao W, Kadia T, Jabbour E, Rausch C, Daver N, Short N, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano K, Wade A, Maduike R, Guerrero J, Vaughan K, Bivins C, Pierce S, Ning J, Ravandi F, Kantarjian M, Konopleva M. Ten-day Decitabine with Venetoclax vs. Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. Cancer 2021 Nov 15(127(22)):4213-4220, 2021. PMID: None.
Maiti A, DiNardo CD, Wang SA, Jorgensen JL, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano K, Pierce SA, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. Blood 5(7):1876-83, 2021. PMID: None.
Desikan S, Ravandi F, Pemmaraju N, Konopleva MY, Loghavi S, Borthakur G, Jabbour E, Daver N, Jain N, Chien KS, Maiti A, Montalban Bravo G, Kadia T, Kwari M, Kantarjian HM, Short NJ. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation. Blood(138 (Supplement 1): 4436), 2021. PMID: None.
K Yamatani K, Y Tabe Y, A Maiti A, T Ai T, K Saito K, K Nitta K, S Kinjo S, K Ikeo K, T Miida T, C DiNardo C, X Su X, M Konopleva M. Diverse Mechanisms of Resistance to Decitabine and Venetoclax Therapy in Newly Diagnosed and Relapsed/Refractory AML Inferred By Transcriptome Analysis. Blood(138 (Supplement 1): 2244), 2021. PMID: None.
Maiti A, DiNardo CD, Qiao W, Kadia T, Jabbour E, Rausch C, Daver N, Short NJ, Borthakur G, Pemmaraju N. AML-297: Ten-Day Decitabine with Venetoclax vs Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score-Matched Analysis. Clinical Lymphoma Myeloma and Leukemia 2021(21):S303, 2021. PMID: None.
Daver N, Konopleva M, Maiti A, Kadia T, DiNardo C, Loghavi S, Pemmaraju N, Jabbour E, Montalban Bravo G, Tang G, Sasaki K, Borthakur G, Yilmaz M, Alvarez J, Golez M, Pierce S, Nogueras González G, Ning J, Abbas H, Ravandi F, Garcia-Manero G, Kantarjian HM. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood 2021(138 (Supplement 1)):371, 2021. PMID: None.
Maiti A, Andreeff M, Konopleva M. Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. None 21:S3-S6, 2021. PMID: None.
Lachowiez C, Takahashi K, Loghavi S, Xiao L, Kadia T, Adeoti M, Short N, Sasaki K, Wang S, Borthakur G, Issa GC, Maiti A, Alvarado Y, Pemmaraju N, Montalban-Bravo G, Masarova L, Yilmaz M, Jain N, Kantarjian HM. AML-204: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Blood 2021(138, Supplement 1):701, 2021. PMID: None.
Mohamed S, Assi R, Ning J, Xiao L, Jabbour E, Pemmaraju N, Kadia T, Jain N, DiNardo C, Yilmaz M, Maiti A, Issa GC, Short NJ, Bose P, Masarova L, Garcia Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Daver N. Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis. Blood(138 (Supplement 1): 1213), 2021. PMID: None.
Yilmaz M, Kantarjian HM, Muftuoglu M, DiNardo CD, Kadia TM, Konopleva MY, Borthakur G, Pemmaraju N, Short NJ, Alvarado Y, Maiti A, Montalban-Bravo G, Jurisprudenica C, Pike A, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML). Hemasphere 2021(6):28-29, 2021. PMID: None.
Venugopal S, Jabbour E, Pemmaraju N, Montalban-Bravo G, Chien KS, Daver N, Jain N, Burger JA, Alvarado Y, Maiti A, DiNardo CD, Borthakur G, Malla R, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials. Blood(138 (Supplement 1): 4420), 2021. PMID: None.
Venugopal S, Kantarjian HM, Maiti A, Short NJ, Montalban Bravo G, Alvarado Y, Chien KS, Kanagal Shamanna R, Pemmaraju N, Daver N, Kadia T, Borthakur G, Jabbour E, Garcia Manero G. A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment‐Naïve High‐Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 2021(138 (Supplement 1)):245, 2021. PMID: None.
Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol 2021(14(1)):1-10, 2021. PMID: None.
Venugopal S, Kadia T, Ravandi F, DiNardo C, Daver N, Borthakur G, Konopleva MY, Garcia Manero G, Montalban Bravo G, Maiti A, Yilmaz M, Issa GC, Chien K, Pierce S, Kantarjian HM, Short NJ. Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML. Blood 2021(138 (Supplement 1)):794, 2021. PMID: None.
Venugopal S, Loghavi S, DiNardo CD, Konopleva MY, Kadia T, Bhalla K, Issa GC, Ravandi F, Daver N, Borthakur G, E Jabbour J, Montalban-Bravo G, Yilmaz M, Chien K, Maiti A, Kantarjian HM, Short NJ. RUNX1 MUTATIONS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA DO NOT ADVERSELY IMPACT. Hemasphere, 2021. PMID: None.
Short NJ, Montalban-Bravo G, Alvarado Y, Konopleva MY, Jabbour E, Garcia-Manero G, Yilmaz M, Jain N, Borthakur G, DiNardo CD, Daver N, Issa GC, Ohanian M, Pemmaraju N, Sasaki K, Maiti A, Chien KS, Ravandi F, Kadia TM, Andreeff M, Muftuoglu M, Delumpa R, Bose P, Pierce S, Waller L, Banks G, Kantarjian HM, Cortes J. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. Blood(138 (Supplement 1)):2349, 2021. PMID: None.
Yilmaz M, Kantarjian HM, Short NJ, Konopleva MY, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Issa GC, Jain NJ, Takahashi K, Sasaki K, Ohanian M, Tang G, Loghavi S, Patel K, Garcia Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML. Blood(138 (Supplement 1)):798, 2021. PMID: None.
Venugopal S, Issa GC, Konopleva MY, DiNardo C, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Andreeff M, Bhalla K, Garcia Manero G, Ravandi F, Kantarjian HM, Daver N. NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). Blood 2021(138 (Supplement 1)):2287, 2021. PMID: None.
Maiti A, DiNardo CD, Daver N, Kadia TM, Borthakur G, Short NJ, Pemmaraju N, Ohanian M, Alvarado Y, Takahashi K, Pierce S, Patel K, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian HM, Konopleva MY. Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax. Blood(2021 Nov 23;138:1304), 2021. PMID: None.
Maiti A, DiNardo CD, Rausch C, Pemmaraju N, Garcia Manero G, Ohanian M, Daver N, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Short NJ, Jabbour E, Montalban Bravo G, Jain N, Kornblau S, Masarova L, Wierda W, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov Z, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson P, Montalbano K, Vaughan K, Bivins C, Pierce S, Qiao W, Ning J, Welch J, Kantarjian HM, Konopleva MY. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Blood 138, 2021. PMID: None.
Alwash Y, Kanagal-Shamanna R, Guerra V, Daver N, Konopleva M, Ravandi F, Kadia T, DiNardo C, Issa G, Borthakur G, Loghavi S, Yilmax M, Maiti A, Kantarjian H, Kornblau K. Development of TP53 Mutations Over the Course of Acute Myeloid Leukemia Therapy. Blood(136):28-29, 2020. PMID: None.
Maiti A, Konoplev S, DiNardo CD Kadia TM, Ravandi F, Daver NG, Pemmaraj N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, AlvaradoY, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano K, Pierce SA, Patel KP, Garcia-Manero G, Kantarjian HM, Konopleva MY. Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine. Blood(136):11-13, 2020. PMID: None.
Zhang Q, Han L, Lodi A, Weng C, Kuruvilla VM, Cavazos A, Ma H, Maiti A, Tabe Y, Marszalek J, Tizani S, Konopleva M. Dual Targeting of Mitochondrial Vulnerability using complex I inhibitor IACS-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in pre-clinical Acute Myeloid Leukemia (AML) models. Blood(136):13-14, 2020. PMID: None.
Kim K, Maiti A, Kadia TM, Ravandi F, Daver NG, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmax M, Alvarado Y, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano KS, Pierce S, Patel KP, Garcia-Manero G, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant Acute Myeloid Leukemia with Venetoclax and Decitabine. Blood(136):33-36, 2020. PMID: None.
Maiti A, Jabbour EJ, Jain N, Borthakur G, Kadia TM, Burger JA, Wierda WG, Konopleva MY, Alvarado Y, Short NJ, Faderl S, O'Brien SM, Ferrajoli A, Kornblau SM, Daver NG, Pemmaraju N, Bose P, Thompson PA, Khoury JD, Balkin H, Kelly M, Azzawi H, Garris R, Garcia-Manero G, Kantarjian HM, Ravandi F. Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial. Blood(136):36-39, 2020. PMID: None.
Maiti A, DiNardo CD, Ravandi F, Pemmaraju N, Borthakur G, Bose P, Issa GC, Kadia TM, Short NJ, Yilmaz M, Montablan-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano KS, Pierce SA, Kantarjian HM, Daver NG, konopleva MY. Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. Blood 2020(136):53-5, 2020. PMID: None.
Maiti, A, DiNardo CD, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Borthakur G, Pemmaraju N, Short NJ, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike R, Guerrero JA, Vaughan K, Bivins CA, Pierce SA, Ravandi F, Kantarjian HM, Konoplev MY. Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. Blood 2020(136):30-3, 2020. PMID: None.
Maiti A, Dinardo CD, Pemmaraju N, Kadia TM, Rausch CR, Naqvi K, Daver NG, Borthakur G, Ohanian M, Issa GC, Alvarado Y, Short NJ, Andreeff M, Jabbour E, Pierce SA, Ravandi F, Garcia-Manero G, Welch JS, Kantarjian HM, Konopleva AM. Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS. Journal of Clinical Oncology 38(15):7519, 2020. PMID: None.
Jain N, Maiti A, Ravandi F, Konopleva M, Alvarado Y, Kadia TM, Short NJ, Borthakur GB, Naqvi K, Pemmarajo N, DiNardo CD, Daver NG, Yilmaz M, Patel KP, Linderman DB, Garris R, Jabbor E, Cortes JE, Kantarjian HM. Inotuzumab Ozogamicin (INO) plus Bosutinib (BOS) in R/R Ph+ ALL or CML in Lymphoid Blast Phase (CML LBP). J Clin Oncol 2020(15):7512, 2020. PMID: None.
Jain N, Maiti A, Ravandi F, Konopleva M, Alvarado Y, Kadia TM, Short NJ, Borthakur GB, Naqvi K, Pemmarajo N, DiNardo CD, Daver NG, Yilmaz M, Patel KP, Linderman DB, Garris R, Jabbor E, Cortes JE, Kantarjian HM. Inotuzumab Ozogamicin With Bosutinib In Relapsed Or Refractory Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Or Chronic Myeloid Leukemia In Lymphoid Blast Phase (CML-LBP). Hemasphere 2020(4):155, 2020. PMID: None.
Kim K, Maiti A, Kadia T, Ravandi F, Daver N, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Alvarado Y, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson P, Rausch C, Montalbano K, Pierce S, Patel K, Garcia-Manero G, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53 -Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine. Blood 2020(136 (Supplement 1)):33-36, 2020. PMID: None.
Zhang Q, Han L, Lodi A, Weng C, Kuruvilla V, Cavazos A, Ma H, Maiti A, Tabe Y, Marszalek J, Tiziani S, Konopleva MY. Dual Targeting of Mitochondrial Vulnerability Using Complex I Inhibitor Iacs-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in Pre-Clinical Acute Myeloid Leukemia (AML) Models. Blood 2020(136 (Supplement 1)):13-14, 2020. PMID: None.
Maiti, A, DiNardo CD, Kadia TM, Rausch CR, Pemmaraju N, Daver NG, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabour EJ, Masarova L, Thompson PA, Pierce SA, Garcia-Manero G, Ravandi F, Welch JS, Qiao W, Ning J, Kantarjian HM, Konopleva MY. 10-Day Decitabine and Venetoclax (DEC10-VEN) Vs. Intensive Chemotherapy (IC) In Acute Myeloid Leukemia (AML): A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Hemasphere 2020(4):22, 2020. PMID: None.
Maiti, A, H Kantarjian H, V Popat V, G Borthakur G, G Garcia-Manero G, M Konopleva M, C DiNardo C, S Verstovsek S, M Andreeff M, T Kadia T, H Ajufo H, R Goswamy R, C Blanco C, M Velasquez M, N Daver N, N Pemmaraju N, S Pierce S, W Wierda W, S Kornblau S, F Ravandi F, J Cortes J. Clinical value of event-free survival in acute myeloid leukemia. Blood 2020(4(8)):1690-1699, 2020. PMID: None.
Maiti A, DiNardo C, Kadia TM, Jabbour E, Rausch C, Daver N, Borthakur G, Pemmaraju N, Short NJ, Yilmaz M, Alvarado Y, Montalbano K, Wade A, Maduike R, Guerrero J, Vaughan K, Bivins C, Pierce S, Ravandi F, Kantarjian HM, Konopleva MY. Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. Blood 2020 Nov 5(136 (Supplement 1)):30-33, 2020. PMID: None.
Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Maneroa G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Afujo HO, Goswami RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce S, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Impact of Stem-Cell Transplantation on Healthcare Utilization in Acute Myeloid Leukemia. Hemasphere None(None):None, 2020. PMID: None.
Maiti A, DiNardo CD, Kadia TM, Pemmaraju N, Kadia TM, Rausch CR, Naqvi K, Daver NG, Borthakur G, Ohanian M, Issa GC, Alvarado Y, Short NJ, Andreeff M, Jabbour E, Pierce SA, Ravandi F, Garcia-Maneroa G, Welch JS, Katnarjian HM, Konopleva M. Ten-day Decitabine with Venetoclax (DEC10-VEN) in AML and High-risk (HR) MDS. J Clin Oncol 2020(38):7519, 2020. PMID: None.
Maiti A, Konoplev S, DiNardo CD, Kadia TM, Ravandi F, Daver N, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Alvarado Y, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson P, Rausch C, Montalbano K, Pierce S, Patel K, Garcia-Manero G, Kantarjian HM, Konopleva MY. Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine. Blood 2020(136 (Supplement 1)):11-13, 2020. e-Pub 2020. PMID: None.
Maiti A, Jabbour E, Jain N, Borthakur G, Kadia TM, Burger JA, Wierda W, Konopleva MY, Alvarado Y, Short NJ, Faderl S, Obrien S, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Bose P, Thompson P, Khoury J, Balkin H, Kelly M, Azzawi H, Garris R, Garcia-Manero G, Kantarjian HM, Ravandi F. Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial. Blood 2020(136 (Supplement 1)):36-39, 2020. PMID: None.
Maiti A, DiNardo C, Ravandi F, Pemmaraju N, Borthakur G, Bose P, Issa GC, Kadia T, Short NJ Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson P, Rausch C, Montalbano K, Pierce S, Kantarjian HM, Daver N, Konopleva MY. Venetoclax, FLT3 Inhibitor and Decitabine in FLT3 mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. Blood 2020(136 (Supplement 1)):53-55, 2020. PMID: None.
Maiti A, DiNardo CD, Wang S, Jorgensen J, Kadia TM, Daver N, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour E, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson P, Verstovsek S, Sasaki K, Andreeff M, Rausch C, Montalbano K, Pierce S, Kantarjian HM, Konopleva MY, F Ravandi F. Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. Blood(136 (Supplement 1)):22-25, 2020. PMID: None.
Alwash Y, Kanagal-Shamanna R, Guerra VA, Daver N, Konopleva M, Ravandi F, Kadia TM, DiNardo CD, Issa GC, Borthakur G, Loghavi S, Takahashi K, Yilmaz M, Maiti A, Kantarjian HM, Short NJ. Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy. Blood 2020(136 (Supplement 1)):28-29, 2020. PMID: None.
Maiti A, Ravandi F, Cortes JE, Jabbour EJ, Marx K, Daver NG, Garcia-Manero G, Konopleva MY, Benton CB, Masarova L, DiNardo CD, Bose P, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP). J Clin Oncol 2019(37):e18515, 2019. PMID: None.
Ball S, Bandyopadhyay D, Hajra A, Ghosh RK, Tijani LA, Maiti A. Thrombotic episodes in myeloproliferative neoplasms: A population based study. J Clin Oncol 2019(37):e18554, 2019. PMID: None.
Bhugra P, Maiti, A, Wu R, Nazarullah AN. Fever in a traveler: Diagnosis with the peripheral smear. J Gen Intern Med 2019(34):S417, 2019. PMID: None.
Maiti, A, Kantarjian HM, Popat V, Blanco C, Velasquez M, Garcia-Manero G, Konopleva MY, Verstovsek Sm Andreeff M, Borthakur G, Kadia TM, Daver NG, Pemmaraju N, DiNardo CD, Pierce S, Wierda W, Kornblau S, Ravandi F, Cortes JE. Clinical Value of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML). J Clin Oncol 2019(37):e18513, 2019. PMID: None.
Maiti, A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Bravo GM, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Rytting ME, Thompson PA, Wang S, Konoplev S, Chen Z, Goswami M, Maduike RE, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, QiaoW, Welch JS, Patel KP, Kantarjian HM, Konopleva MY, DiNardo CD. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia After Frontline Hypomethylating Agent with Venetoclax Regimens. Blood 2019(134):738, 2019. PMID: None.
Maiti, A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Rytting ME, Thompson PA, Wang S, Konoplev S, Chen Z, Goswami M, Maduike RE, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, QiaoW, Welch JS, Patel KP, Kantarjian HM, Konopleva MY, Dinardo CD. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood 2019(134):645, 2019. PMID: None.
Maiti, A, DiNardo CD, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Rytting ME, Thompson PA, Wang S, Konoplev S, Chen Z, Goswami M, Maduike RE, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, QiaoW, Welch JS, Kantarjian HM, Konopleva MY. Ten-day Decitabine with Venetoclax (DEC0-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood 2019(134):2637, 2019. PMID: None.
Karkhanis V, Fiskus W, Mill CP, Maiti, A, Lara BH, Maher JV, Bhalla I, Shao N, Green MR, Khoury JD, Bhalla KN. Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL). Blood 2019(134):3961, 2019. PMID: None.
Maiti, A, Kantarjian HM, Garcia-Manero G, Konopleva MY, Verstovsek S, Andreeff M, Borthakur G, Kadia TM, Daver NG, Pemmaraju N, DiNardo CD, Pierce SA, Xiao L, Huang X, Wierda W, Kornblau S, Ravandi F, Cortes JE. Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy. Blood 2019(134):2614, 2019. PMID: None.
Fiskus WC, Maiti, A, Saenz DT, Mill CP, Khoury JD, Bhalla KN. Targeted therapy evaluation in novel pre-clinical in vitro and in vivo models of Richter transformation [abstract]. Cancer Res 2019(79 (Supplement 13)):1071, 2019. PMID: None.
Bhugra P, Maiti A. A case of potentially fatal epistaxis. J Gen Intern Med 2019(34):S429, 2019. PMID: None.
Bhugra P, Maiti, A. A Quandary of Unresolving Orbital Cellulitis. J Gen Intern Med 2019(34):S449, 2019. PMID: None.
Rausch CR, DiNardo CD, Maiti, A, Jammal N, Kadia T, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo A, Daver N, Chew S, Sasaki K, Issa GC, Naqvi K, Ravandi F, Kantarjian HM, Konopleva MY. Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. Blood 2019(134):2640, 2019. PMID: None.
Ball S, Vutthikraivit W, Das A, Edwards PJ, Short NJ, Maiti A. Risk of Infection with Ibrutinib in Patients with B-cell Malignancies: A Meta-analysis of Phase III Randomized Controlled Trials. Blood 2018(132):2871, 2018. PMID: None.
Roy B, Das A, Maiti A, A Gupta A, Bandypadhyay D. Neuropathy as an adverse effect of vascular endothelial growth factor tyrosine kinase inhibitors, a meta-analysis of randomized clinical trials. Neurology 2018(90):P6.098, 2018. PMID: None.
Maiti A, DiNardo CD, Cortes JE, Borthakur G, Pemmaraju N, Benton CB, Kadia TM, Takahashi K, Naqvi K, Ravandi F, Alvarado Y, Short NJ, Daver NG, Sasaki K, Ohanian MN, Garcia-Manero G, Thompson PA, Kornblau SM, Masarova L, Jain N, Jabbour EJ, Andreeff M, Maduike R, Guerrero JA, Zhang Q, Cavasos A, Ma, H, Rausch CR, Bivins CA, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 2018(132):286, 2018. PMID: None.
Chien KS, Benton CB, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJm Kantarjian HM, Pardanani A, Garcia-Manero G. Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 2018(132):2722, 2018. PMID: None.
Ball S, Vutthikraivit W, Das A, Edwards PJ, Tijani L, Short NJ, Maiti A. Risk of Atrial Fibrillation with Ibrutinib in Patients with B-Cell Malignancies: An Updated Meta-Analysis of Phase III Randomized Controlled Trials. Blood 2018(132):1869, 2018. PMID: None.
Maiti A, Kantarjian HM, Jabbor EJ, Poku R, Yearby BA, Breakefield S, Ravandi F, Cortes JE. Phase I/II Study of Ruxolitinib for Minimal Residual Disease in Chronic Myeloid Leukemia. Blood 2018(132):3009, 2018. PMID: None.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, DiNardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Updated results of a randomized phase II trial of 5-day versus 10-day schedules of decitabine in older patients with newly diagnosed acute myeloid leukemia. Blood 2018(132):84, 2018. PMID: None.
Jiang Y, Maiti A, Kanaan Z. A Young Man with a Mediastinal Mass. Clin Lymphoma Myeloma Leuk 2018(18):S292-3, 2018. PMID: None.
Maiti A, Naqvi K, Kadia T, Borthakur G, Takahashi K, Bose P, Daver N, Patel A, Alvarado Y, Ohanian M, DiNardo C, Jabbour E, Garcia-Manero G, Kantarjian H, Ravandi F. MEK Inhibitor Binimetinib (MEK162) in Relapse and Refractory Acute Myeloid Leukemia: Results of a Phase I/II Study. Clin Lymphoma Myeloma Leuk 2018(18):S199, 2018. PMID: None.
Ball S, Vutthikraivit W, Maiti A, Short NJ. Risk of Infection with Ibrutinib in patients with Chronic Lymphocytic Leukemia (CLL): A systematic review and meta-analysis of phase III randomized controlled trials. Clin Lymphoma Myeloma Leuk 2018(18):S215, 2018. PMID: None.
Ball S, Maiti A, Arevalo M, Das A, Vutthikraivit W, Edwards PJ, Hardwicke F. Risk of Bleeding with Ibrutinib in Patients with B-Cell Malignancies: An Updated Meta-Analysis of Phase III Randomized Controlled Trials. Blood 2018(132):5553, 2018. PMID: None.
Maiti A, Kantarjian HM, O’Brien S, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Borthakur G, Jain N, Konopleva M, Sasaki K, Pemmaraju K, Alvarado Y, Jacob J, Garris R, Thompson P, Cortes JE, Jabbour EJ. Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial. Clin Lymphoma Myeloma Leuk 2017(17):S255-S256, 2017. PMID: None.
Maiti A, Kantarjian HM, Ravandi F, Khouri M, Thomas DA, Garcia-Manero F, Garris RS, Cortes JE, Short NJ, Jain N, Bose P, Verstovsek S, Konopleva MY, Sasaki K, Issa GC, Ghosn M, Schroeder HM, Kadia TM, Daver NG, O’Brien SM, Jabbour EJ. Hyper-CVAD Plus Ofatumumab as Frontline Therapy in CD0+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. Blood 2017(130):3876, 2017. PMID: None.
Maiti A, Kantarjian HM, Ravandi F, Thomas DA, Khouri M, Garcia-Manero G, Garris RS, Cortes JE, Short NJ, Sasaki K, Issa GC, Koller PB, Schroeder HM, Kadia TM, Verstovsek S, Daver NG, Jain N, Konopleva MY, O’Brien SM, Jabbour EJ. Frontline Ofatumumab with Hyper-CVAD in CD0+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Clin Lymphoma Myeloma Leuk 2017(17):S256-7, 2017. PMID: None.
Maiti A, Kantarjian HM, Popat V, Garcia-Manero G, Konopleva M, Verstovsek S, Andreeff M, Borthakur G, Kadia T, Daver N, Pemmaraju N, DiNardo C, Pierce C, Wierda W, Kornblau S, Ravandi F, Cortes JE. The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right?. Blood 2017(130):4693, 2017. PMID: None.
Ko HC, Yan M, Gupta R, Song J, Kebbel K, Maiti A, Nates JL, Overman MJ. Predictors of Survival in Patients with Gastrointestinal Malignancies Admitted to the Intensive Care Unit. J Clin Oncol 2017(35):e181449, 2017. PMID: None.
Maiti A, Kantarjian HM, Ravandi F, Thomas FA, Khouri M, Garcia-Manero G, Garris RS, Cortes JE, Short NJ, Sasaki K, Issa GC, Koller PB, Schroeder HM, Kadia TM, Verstovsek S, Daver NG, Jain N, Konopleva M, O'Brien SM, Jabbour E. Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia. J Clin Oncol 2017(35):abstr 7033, 2017. PMID: None.
Kukreja K, Keshav, MD; Meriwether M, Maiti A, Faruki A, Salahudeen A, Rahimi E. Stuck in the Gut. An Unusual Duodenal Bezoar Following Pyloric-exclusion Gastrojejunostomy:2465. Am J Gastroenterol 2017(112):S1342-S1343, 2017. PMID: None.
Herman A, Maiti A. Complications of the Heimlich Maneuver: A Case of Traumatic Gastric Diaphragmatic Herniation: 2582. Am J Gastroenterol 2017(112):S1411-S1412, 2017. PMID: None.
Maiti A, Kantarjian HM, Short NJ, Khouri M, Takahashi K, Ohanian M, Borthakur G, Konopleva MY, Daver NG, Estrov Z, Alvarado Y, Thompson P, Jain N, Ravandi F, Garcia-Manero G, Cholick C, Khouri R, O’Brien S, Jabbour EJ. Blinatumomab in B-cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease: Interim Results of a Phase II Trial. Blood 2017(130):5038, 2017. PMID: None.
Maiti A, Kantarjian HM, Ravandi F, Short NJ, Daver NG, Pemmaraju N, Thomas DA, Yilmaz M, Kadia TM, Sasaki K, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Estrov Z, Jain N, Wierda WG, Jeanis V, Cortes JE, O’Brien S, Jabbour EJ. Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Clin Lymphoma Myeloma Leuk 2017(17):S257-8, 2017. PMID: None.
Benton CB, Diaz-Pavon JR, Maiti A, Daver NG, Ravandi F, Jain N, Alvarado Y, Jabbour E, Pierce S, Kwari M, Santos MA, Martinez S, Siguero M, Tefferi A, Cortes JE, Kantarjian HM, Pardanani AD, Garcia-Manero G. Phase I study of lurbinectedin (PM11083) in patients with advanced AML and MDS. J Clin Oncol 2017(35):e18521, 2017. PMID: None.
Maiti A, Short NJ. A Blue Finger and Hyponatremia Leading to a Diagnosis of Malignancy-Associated Marantic Endocarditis. J Gen Intern Med 2016(31):S484, 2016. PMID: None.
Jabbour E, Short NJ, Huang X, Maiti A, Kadia T, Daver N, Borthakur G, DiNardo C, Pemmaraju N, Sasaki K, Estrov Z, Verstovsek S, Ravandi F, Alvarado Y, Sekeres, MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Miller D, Pierce S, Kantarjian H, Garcia-Manero G. A Randomized Phase II Study of Low-Dose Decitabine versus Azacytidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. Blood 2016(128):226, 2016. PMID: None.
Maiti A, Kantarjian H, Patel K, Borthakur G, Ravandi G, Verstovsek S, Ferrajoli A, Estrov Z, Kadia T, Skinner J, Poku R, Dellasala S, Luthra R, Jabbour E, Cortes J. Long Term Follow-up of Frontline Dasatinib in Patients (Pts) with Early Chronic Phase Chronic Myeloid Leukemia (CML-CP). J Clin Oncol 2016(34):e18542, 2016. PMID: None.
DeCicco IA, Maiti A, Aisenberg G. Actinomycoses, An Unusual Suspect for Non-Resolving Pneumonia. J Gen Intern Med 2016(31):S536-7, 2016. PMID: None.
Maiti A, Verstovsek S, Powers CA, Fullmer CP, Reyes SR, Bueso-Ramos C, Short NJ. Quality and cost comparison of powered versus manual bone marrow biopsy devices at a large U.S. cancer center. J Clin Oncol 2016(34):e18283, 2016. PMID: None.
Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Maiti A, Konopleva M, DiNardo C, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong XQ, Cortes J, Kantarjian H, Jabbour E. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood 2016(128):4328, 2016. PMID: None.
Saha D, Maiti A, F Khan F, Rodriguez E. Successful Treatment of Early Stage Monophasic Pulmonary Synovial Sarcoma with Minimally Invasive Robotic Video-assisted Lobectomy. Am J Respir Crit Care Med 2016(193):A6027, 2016. PMID: None.
Maiti A, Kinahan H, Hess K, Baldwin S, Dempsey J, AbadieL, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Falchook G, Subbiah V. Characteristics and outcomes of patients with solid tumors undergoing investigational therapies who are discharged to hospice after an inpatient admission. J Nat Compr Canc Netw 2016(14):e-19-20, 2016. PMID: None.
Maiti A, Kantarjian H, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O’Brien S, Cortes J. Homoharringtonine with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia. Blood 2016(128):5449, 2016. PMID: None.
Saha D, Basu A, Maiti A, Narvaez SG, Medina AM, Rodriguez E. Successful Trial of Doublet Adjuvant Chemotherapy in A Case of Primary Proximal Epithelioid Sarcoma of the Lung. Am J Respir Crit Care Med 2015(191):A3605, 2015. PMID: None.
Benton CB, Short N, Hokanson J, Pierce S, Gonzalez GN, Maiti A, Min TL, Konopleva M, Kadia T, Cortes J, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Andreeff M. Optimized Voronoi compartment determination using machine-learning to identify prognostic groups of patients based on cellular behavior in treated AML. Clin Lymphoma Myeloma Leuk 2015(15):S22, 2015. PMID: None.
Maiti A, Chatterjee S. Experience of congenital adrenal hyperplasia in eastern India from 1996 to 2010. Endocr Rev 32(None):P2-738, 2011. PMID: None.

Book Chapters

Maiti A, Andreeff M. Emerging approaches to treat high-risk acute myeloid leukemia. In: Diagnostic and management of high-risk acute myeloblastic leukemia in adult patients. None. Minerva Medica, None, 2023.

Letters to the Editor

Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, Kadia, TM, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13, 2023.
Ball S, Vutthikraivit W, Maiti A, Short NJ. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?. Eur J Haematol 101(3):418-420: 418-420, 2018.
Ganguly, A, Maiti, A. Letter to the editor. Australasian Medical Journal 5: 32, 2012.

Less

Grant & Contract Support

Title:	Targeting MerTK using novel antibody drug conjugate RGX-019 in AML
Funding Source:	Inspirna
Role:	CO-I

Title:	Brandon DeLeon Memorial Fund
Funding Source:	Philanthropy
Role:	PI

Title:	Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK cells for Acute Myeloid Leukemia
Funding Source:	University of Texas MD Anderson Cancer Center
Role:	PI

Title:	Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
Funding Source:	Gateway for Cancer Research
Role:	PI

Title:	Arming NK Cells to Target B7-H3+ AML Cells
Funding Source:	Leukemia Lymphoma Society
Role:	Co-I

Title:	Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
Funding Source:	Chimeric Therapeutics
Role:	PI

Title:	Protocol 2022-0509: A Phase I/II Dose Escalation and Expansion Study of BST-236 plus Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Induction Chemotherapy
Funding Source:	BioSight Ltd
Role:	PI

Title:	Protocol 2021-0877 A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia
Funding Source:	Sanofi-Aventis
Role:	PI

Title:	Protocol 2022-0542: Phase I study of IGM-8444 with Azacitidine and Venetoclax, or Birinpant in Relapsed, Refractory, or Newly Diagnosed AML
Funding Source:	IGM Biosciences
Role:	PI

Title:	Protocol 2021-0451: Phase 2, Study of BST-236 Older/Unfit Patients with Relapsed or Refractory Acute Myeloid Leukemia or HR-MDS
Funding Source:	BioSight Ltd
Role:	PI

Title:	Protocol 2021-0248: Phase II Study of Venetoclax in Combination with 10-day Oral Decitabine in Relapsed/Refractory Acute Myeloid Leukemia
Funding Source:	Astex Pharmaceuticals
Role:	PI

Title:	Protocol 2019-0591: Phase 1b Study of Venetoclax in Combination with Intensive Induction and Consolidation Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia
Funding Source:	Dana Farber Partners Cancer Care, Inc
Role:	PI

Title:	Protocol 2017-0912: A Phase II Study of Venetoclax in Combination with 10-day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia, Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm
Funding Source:	M.D. Anderson Cancer Center
Role:	PI

Title:	Armored Allogeneic CAR Gamma Delta T Cell Targeting CD70 for Acute Myeloid Leukemia with Relapsed/Refractory or Measurable Residual Disease
Funding Source:	CPRIT
Role:	PI

Title:	Armored Allogeneic CAR Gamma Delta T Cell Targeting CD70 for Acute Myeloid Leukemia with Relapsed/Refractory or Measurable Residual Disease
Funding Source:	DOD
Role:	PI

Title:	Armored Allogeneic CAR gd T Cell TargetingCD70 for Acute Myeloid Leukemia
Funding Source:	GFCR
Role:	PI

Title:	LOI - Investigating Novel Therapeutics in Acute Myelogenous Leukemia and Response Correlation in Patients with African Ancestry
Funding Source:	Leukemia Lymphoma Society
Role:	Co-I

Title:	Protocol 2022-0581: Understanding the combinational effect of CDC7 inhibition with hydroxyurea in acute myeloid leukemia
Funding Source:	Lin BioSciences Inc
Role:	PI

Title:	Anti-PR1 Antibody Therapy for Advanced Myeloid Leukemias
Funding Source:	Conquer Cancer Foundation, ASCO
Role:	PI

Title:	Targeting Integrated Stress Response to Overcome Venetoclax Resistance in Acute Myeloid Leukemia
Funding Source:	Leukemia & Lymphoma Society
Role:	PI

Title:	Mechanisms of Venetoclax Resistance in AML - Aim 3: Phase I Trial of Devimistat, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Funding Source:	Leukemia Lymphoma Society
Role:	Co-I

Title:	Combining Eoigenetic, Apoptosis Targeting, and Adoptive Cellular Therapy in Adverse Risk Acute Myeloid Leukemia
Funding Source:	DKMS
Role:	PI

Title:	Combining Epigenetic, Apoptosis Targeting, and Adoptive Cellular Therapy for Adverse Risk Acute Myeloid Leukemia
Funding Source:	John Hansen Research Grant
Role:	PI

Title:	Dual Targeting of Mitochondrial Vulnerability in Acute Myeloid Leukemia Using A First-in-class Anti-mitochondrial Agent Devimistat with Bcl-2 Inhibitor Venetoclax, and Azacitidine
Funding Source:	American Society of Hematology (ASH)
Role:	PI

Title:	Genomic Characterization of Resistance to Anti-apoptotic and Hypomethylator Therapy in Acute Myeloid Leukemia
Funding Source:	ECOG-ACRIN
Role:	Postdoctoral Fellow

Title:	Characterization of Immunobiology of Chronic Myeloid Leukemia to Inform Novel Immunotherapeutic Approaches
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	Investigator

Title:	Bcl-2 Inhibitor Venetoclax in Combination with Intensive Chemotherapy FLAG-IDA in Acute Myeloid Leukemia
Funding Source:	Dorris Duke Charitable Foundation
Role:	PI

Title:	Phase Ib Trial of Azacitidine, Venetoclax and NK Cells in AML
Funding Source:	Sabin Fellowship
Role:	Principal Investigator-MDACC

CV information above last modified December 18, 2024

Abhishek Maiti, MD

About Dr. Abhishek Maiti

In the News

ASCO: Developing effective combination therapies for leukemia

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Abhishek Maiti, MD

About Dr. Abhishek Maiti

In the News

ASCO: Developing effective combination therapies for leukemia

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer